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ABSTRACT 
Thiazole/oxazole-modified microcins (TOMMs) comprise a family of ribosomally synthesized 
and post-translationally modified peptides (RiPPs) that all contain thiazole and oxazole 
heterocycles derived from cysteine, serine, and threonine residues, respectively. The 
thiazole/oxazole heterocycle is installed over two distinct steps. First, the cyclodehydratase 
cyclizes an unmodified cysteine, serine, or threonine residue to a thiazoline or oxazoline 
heterocycle, which can be oxidized by a FMN dependent dehydrogenase to afford a thiazole or 
oxazole heterocycle. The biosynthesis of a number of TOMMs has been investigated (Chapter 
1), yet a number of fundamental questions regarding substrate processing remained. Genome 
mining efforts revealed an uncharacterized TOMM gene cluster in Bacillus sp. Al Hakam (Balh) 
that contained substrates and enzymes that ultimately overcame previous limitations. Initial 
reconstitution of the enzymes revealed cyclization of half of the heterocyclizable residues. This 
observation inspired a series of experiments to explain the observed selectivity. Using a 
combination of high-resolution mass spectrometry, site-directed mutagenesis, and kinetics, I 
found that the location of a heterocyclizable residue and the presence of a preceding glycine 
largely dictate heterocycle formation, which uniquely proceeds in an overall C- to N-terminal 
fashion (Chapter 2). While characterizing the cyclodehydratase, it became evident that omission 
of the dehydrogenase had no effect on cyclodehydratase activity. This provided the opportunity 
to separate the function of the two enzymes and investigate how the dehydrogenase interacts 
with the cyclodehydratase and processes substrate (Chapter 3). Many of the tools I developed to 
study the Balh TOMM synthetase proved useful for structural and biosynthetic studies of other 
RiPPs (Appendix A). 
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Chapter 1: Introduction 
This chapter was adapted in part from Melby et al.1 Reprinted from Current Opinion in Chemical 
Biology, 15, Joel O. Melby, Nathan J. Nard, Douglas A. Mitchell, Thiazole/oxazole-modified 
microcins : complex natural products from ribosomal templates, 369-378, Copyright 2011, with 
permission from Elsevier. 
 
I am grateful to Nathan Nard for greatly assisting the phylogenetic analysis.  
 
1.1 Thiazole/oxazole-Modified Microcins 
One strategy that has Nature employs in the production of biologically active secondary 
metabolites uses existing machinery to synthesize inactive precursor peptides. Upon 
posttranslational modification, these inactive precursors undergo structural rigidification and are 
endowed with function. The major advantages to this strategy are i. producer organisms did not 
need to start from scratch as all organisms possess ribosomes, ii. amino acid mutations, which 
provide chemical diversity, occur at the genomic level by simple changes in the codons, and iii. 
conversion of inactive precursors to active products could be temporally and spatially controlled 
at the posttranslational level, allowing organisms to respond quickly to environmental changes. 
Two major classes of peptide-derived natural products follow the above strategy: the 
lantipeptides and the TOMMs. The lantipeptides contain (methyl)lanthionine crosslinks, which 
are installed through the Michael-type addition of a cysteine thiol to a dehydrated serine or 
threonine.2 In the TOMM class of natural products, cysteine, serine, and threonine residues are 
heterocyclized, which conformationally restrains the flexibility of the peptide.  
Indeed, thiazole and oxazole heterocycles are ubiquitous in bioactive molecules and show 
impressive functional versatility in TOMM, non-TOMM, and synthetic products. A few 
examples include thiostrepton (50S ribosome inhibitor), 3 trunkamide (anti-cancer compound),4  
microcin B17 (DNA gyrase inhibitor), 5 goadsporin (secondary metabolism inducer),6 
yersiniabactin (siderophore),7 and Ritonavir (HIV-1 protease inhibitor)8 (Figure 1.1). Thus, it is 
not surprising that Nature has devised two enzymatic solutions to construct thiazol(in)es and 
oxazol(in)es, one of which operates on non-ribosomal peptides and the other on ribosomal 
peptides (TOMMs). In both systems, cyclodehydration converts amino acids with a beta-
nucleophile (cysteine, serine, or threonine) into thiazoline or (methyl)oxazoline rings.9, 10 Select 
azoline rings can then be oxidized to azoles, which in characterized cases is catalyzed by a flavin 
mononucleotide (FMN) –dependent dehydrogenase.9, 11 The nonribosomal peptide synthetase 
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(NRPS) and TOMM enzymes that catalyze the cyclodehydration bear no amino acid similarity to 
each other and present an example of convergent evolution in biosynthetic processes.  
In addition to the cyclodehydratase and optional dehydrogenase, all characterized TOMM 
clusters contain a “docking protein”. The precise role of the docking protein has been debated, 
but the available data suggest that it plays a direct role in regulating cyclodehydratase activity 
and assembly of an active synthetic complex.12, 13 Despite this unclear role in TOMM 
biosynthesis, Nature has given us a hint as to the importance of the docking protein by fusing this 
gene to the C-terminus of the cyclodehydratase in approximately half of all known TOMM 
clusters. In the other cases, the cyclodehydratase is found as a separate open reading frame but is 
expected to form a complex with the docking protein, as demonstrated in microcin B17 
biosynthesis.9 Beyond the heterocyclization machinery, TOMM clusters can also possess other 
posttranslational modification enzymes, a topic discussed later in this chapter.  
Akin to the other classes of ribosomal natural products, all characterized TOMM 
precursor peptides are bipartite. The N-terminal region of the precursor peptide, known as the 
leader peptide, contains key recognition motifs for the biosynthetic machinery.14 The C-terminal 
region of the precursor peptide, referred to as the core peptide, is rich in heterocyclizable 
residues and can be the site of numerous other posttranslational modifications.14 From the 
perspective of the producing organism, diversification of a TOMM is expected to be facile due to 
the relative ease of altering the composition of the core peptide.15 As long as key binding sites 
are present within the leader peptide, the synthetase complex will carry out heterocyclization 
reactions on highly variable core peptides due to its promiscuous nature.16-18 NRPS-derived 
natural products are expected to require a much more substantial genetic rearrangement to 
produce alternative compounds.19 
In this thesis, I use “TOMM” as an umbrella term to refer to all ribosomal peptides 
posttranslationally modified by proteins with identifiable amino acid similarity to known 
cyclodehydratases. Such natural products have appeared in several recent reviews.2, 3, 15, 20-28 This 
chapter, however, will focus on the biosynthesis and the natural combinatorial diversity of the 
TOMM family. 
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Figure 1.1 The biosynthesis and structure of thiazole/oxazole containing compounds.  (a) 
Thiazoles and oxazoles are installed by peptide backbone cyclodehydration of a cysteine, serine, 
or threonine residue, resulting in a thiazoline or (methyl)oxazoline ring.  A FMN-dependent 
oxidation then yields the thiazole or (methyl)oxazole ring. (b) Representative examples of 
biologically active thiazole/thiazoline/oxazole-containing compounds. Those that are TOMMs 
have a black carbon skeleton, while those that are non-TOMMs have a grey carbon skeleton. The 
latter are either products of a nonribosomal peptide synthetase or are of artificial synthetic origin.  
Azoles and azolines are colored in green and red, respectively, while other posttranslational 
modifications are blue. As specifically mentioned in the main text: Microcin B17, the 10-glycine 
spacer is underlined and bolded, while the first bisheterocycle site is boxed; Thiostrepton, 
alanines 2 and 4 are highlighted in orange and brown, respectively. 
 
1.2 Microcin B17: The Grandfather TOMM 
 The general biosynthetic route for the production of microcin B17 (Figure 1.1), a TOMM 
from select strains of Escherichia coli, was first reported in 1996.9 In this seminal paper, it was 
shown that a trimeric synthetase complex composed of McbB (cyclodehydratase), McbC 
(dehydrogenase), and McbD installed thiazole and oxazole moieties onto the McbA precursor 
peptide. This first enzymatic insight into the maturation of microcin B17 prompted numerous 
additional studies. In one such study, site-directed mutagenesis was used in conjunction with 
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western blotting and mass spectrometry (MS) to biochemically dissect how the first 
bisheterocycle site was formed (Gly-Ser-Cys-Gly, boxed in Figure 1.1).	   In vitro experiments 
suggested that the cysteine cyclized first, which then proceeded to the bisheterocycle.  Alteration 
of the bisheterocycle site to Gly-Cys-Ser-Gly (Ser/Cys order reversed) did not mature to the 
bisheterocycle and predominantly formed only the one thiazole ring species.29 This was a 
relevant observation since a naturally occurring Gly-Cys-Ser-Gly sequence resulted in a 
bisheterocycle elsewhere on the McbA peptide (Figure 1.1). Clearly, heterocycle formation was 
not just dependent on the cyclizable residue, but also on the flanking residues. The glycine 
before the first bisheterocycle site proved to be crucial for heterocycle formation, as mutation of 
this residue to alanine precluded heterocycle formation.30 Replacement of the C-terminal 
flanking glycine had a lesser effect. When mutated to alanine, valine, or asparagine, heterocycle 
formation was observed, although the rate was diminished by approximately two-fold in the 
valine and asparagine mutations.30 Also, it was shown that cysteine residues cyclize 100-fold to 
1000-fold faster than serine residues, depending on their location.31 The increased rate was 
presumably due to the increased nucleophilicity and acidity of thiols, relative to alcohols. There 
also appeared to be a distance dependence on microcin B17 heterocycle formation. Upon 
shortening of the naturally occurring 10-glycine linker region between the leader sequence and 
the core domain (boldface/underlined in Figure 1.1), a decrease in the rate of heterocyclization 
was observed. Likewise, a two-fold increase in rate was observed when the linker was 
lengthened to 11-glycines (Figure 1.1).30 The order of heterocycle formation was also determined 
for microcin B17 via tandem MS. Overall, the installation of heterocycles was found to be 
directional, from the N-terminus to C-terminus. Furthermore, McbBCD released the McbA 
substrate after each heterocycle was formed, making microcin B17 biosynthesis a distributive 
process.32 From all of these biochemical studies, it was evident that the microcin B17 
biosynthetic machinery displayed regiospecific activity. However, this interpretation is 
somewhat convoluted due to the fact that in the N-terminal to C-terminal direction, four of the 
first five cyclizable residues encountered are cysteines, which are inherently more reactive 
(Figure 1.1).  
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1.3 Cyanobacteria: Marine Medicinal Chemists at Work 
 The cyanobactins are a large family (>100) of macrocyclized TOMMs produced by 
cyanobacteria (e.g. trunkamide, Figure 1.1).18, 33, 34 A landmark discovery established that 
patellamides A and C were not being produced by the sea squirt (Lissoclinum patella), as was 
long suspected, but instead originated from its cyanobacterial symbiont (Prochloron didemni). 
Moreover, this report proved that these metabolites were of ribosomal origin. 35 Since this initial 
discovery, the biosynthetic gene clusters for many cyanobactins have been identified,18, 33, 36, 37 
some of which appear to have been distributed through horizontal gene transfer.38 Additional 
studies with patellamide and trunkamide determined that the heterocycles were installed in a 
manner similar to microcin B17, supporting the classification of the heterocycle-containing 
cyanobactins as TOMMs. One key difference is that, unlike microcin B17, the cyanobactin 
hypervariable core peptides are flanked by highly conserved motifs. These motifs serve as 
proteolytic cleavage sites that ultimately lead to macrocyclization by an enzyme resembling 
subtilisin.39  
The cyanobactins provide a remarkable example of natural combinatorial biosynthesis, as 
illustrated by the variation at every position of the core peptide (Figure 1.2). The least variance is 
observed at the C-terminus of the core peptide where a heterocycle is always found.34 
Interestingly, the penultimate position never contains a heterocyclizable residue. It remains 
unclear if the resulting molecules would be either biologically inactive or the biosynthetic 
machinery cannot carry out the transformation due to spatial considerations. A typical 
cyanobactin precursor peptide will contain two core peptides, allowing for the production of 
multiple cyanobactins from a single polypeptide.14 This natural library displays remarkable 
chemical diversity and supports the notion that the biosynthetic enzymes are permissive in their 
substrate tolerance. This inherent substrate flexibility allows for variation to emerge in the core 
domain and for new products with enhanced activity or novel modes of action. If the substrate 
tolerance and specificity of each cyanobactin modifying enzyme were known, it would allow the 
rational design of substrates to give rise to a desired product.  
As the first steps towards the rational engineering of cyanobactins, preliminary 
biochemical work has been done on PatD and TruD. These heterocyclization enzymes are single 
polypeptide fusions of the cyclodehydratase and docking proteins (CD fusion) from the 
patellamide and trunkamide biosynthetic clusters, respectively.40, 41 These two proteins are 88% 
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identical at the amino acid level, with essentially all of the differences occurring in the C-
terminal docking protein domain.40  Given their similarity, it is quite surprising that PatD and 
TruD have different regiospecificities. After heterocyclization and prenylation, cyanobactins 
must be proteolytically cleaved from the precursor peptide and macrocyclized. In the patellamide 
biosynthetic cluster, PatA and PatG were shown to cleave the N-termini and C-termini of the 
core peptide, respectively.39  PatG also catalyzed the final macrocyclization reaction through a 
proposed transamidation mechanism.39, 42 PatG, which exhibits a broad substrate scope, catalyzed 
the proteolytic cleavage and macrocyclization of synthetic peptides of varying length and 
composition, even peptides containing nonproteinogenic residues.42 An early demonstration of 
this enzymatic promiscuity was illustrated by engineering the production of eptidemnamide, an 
entirely artificial substrate similar to the antiplatelet drug, eptifibatide.18 Again, the inherent 
substrate tolerance of the modifying enzymes permits for rapid alteration of the natural product 
at the genetic level. Thus, TOMMs can be re-tailored to meet organismal demands upon 
encountering environmental challenges.  
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Figure 1.2 Phylogenetic analysis of the cyanobactins and thiopeptides. (a) A comparative 
analysis of the cyanobactins using the publicly available precursor peptide sequences. The core 
regions of the precursor peptides were used to generate a sequence logo for each clade. In the 
uncharacterized clades, sequence alignment was used to hypothesize the protease cleavage sites. 
The least variance is present in the last position of the core peptide, which is predominantly a 
cysteine that becomes a thiazol(in)e. (b) Same as above, except the thiopeptide precursor 
peptides were used for the analysis. The clades were classified to bind the 50S ribosomal subunit 
or elongation factor Tu based on characterized members. All phylogenetic analyses were 
conducted using MEGA443 and all sequence logos were produced using WebLogo.44 
 
1.4 Streptolysin S-like Toxins: Disease-promoting TOMMs 
 For over a century, scientists have repeatedly sought to isolate and characterize the factor 
responsible for the classic, β-hemolytic phenotype exhibited by S. pyogenes.45 Early efforts were 
met with limited success due to the frustrating biophysical characteristics and non-antigenic 
nature of streptolysin S (SLS). A pioneering discovery in 1998 identified the first SLS-associated 
gene (sagA) and led to the discovery of the entire sag operon.46, 47 Further studies demonstrated 
that the biosynthetic gene cluster required for SLS production was composed of a dehydrogenase 
(SagB), a cyclodehydratase (SagC), and a docking protein (SagD), which act collectively to 
install thiazole and oxazole heterocycles onto an inactive precursor peptide (SagA).45 After 
heterocycle installation by in vitro reconstitution, SagA was converted into a broadly active 
cytolysin, providing the first molecular level description of the factor responsible for the β-
hemolytic phenotype of S. pyogenes.45 Given that the biosynthetic route to SLS was highly 
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reminiscent of microcin B17, it was subsequently demonstrated that reacting McbA with 
SagBCD resulted in the formation of heterocycles on McbA, again highlighting the enzymatic 
promiscuity of the TOMM machinery.45 As with the early studies on SLS, the problematic amino 
acid composition of SagA thwarted numerous modern MS methods to identify sites of 
posttranslational modification after reaction with SagBCD. However, a Herculean effort, 
involving derivatization of SagBCD-treated SagA, followed by tandem MS, and extensive data 
analysis demonstrated that SagBCD installed heterocycles onto the SagA core peptide.48 
Similarity to the sag operon provided genetic evidence that SLS-like toxins may promote the 
virulence of non-Streptococcal human pathogens (Clostridium botulinum, Listeria 
monocytogenes, and Staphylococcus aureus), which have since been experimentally validated to 
be cytolytic using a combination of genetic deletions and in vitro reconstitution.17, 48, 49 
The promiscuity observed with cyanobactin biosynthesis is echoed in the cytolytic 
TOMMs. This was first illustrated by the ability of SagBCD to install heterocycles onto McbA 
and the SagBCD-dependent conversion of the precursor peptide from C. botulinum (ClosA) into 
a potent cytolysin.45 However, incubating the precursor peptides of S. aureus and L. 
monocytogenes (StaphA and ListA, respectively) with SagBCD or complementing their genes 
into a ∆sagA S. pyogenes strain did not result in cytolytic activity.17 Upon further study, it was 
established that although the heterocycle-forming enzymes tolerate diverse substrates, specificity 
is achieved by the leader peptides having distinct binding motifs, which direct the precursor 
peptide to the biosynthetic machinery.14, 17, 50 The requirement of these binding motifs prevents 
the heterocyclization of all cellular peptides and proteins, which would presumably be lethal to 
the producing organism. Therefore, cytolytic activity was not observed with StaphA and ListA 
because their leader peptides lack important binding motifs recognized by SagBCD.14, 17 Further 
studies utilizing chimeric precursor peptides containing the SagA leader peptide and the StaphA 
and ListA core peptides resulted in cytolytic activity after treatment with SagBCD.17 The 
promiscuity of the SagBCD complex has also been further illustrated by the processing of 
artificial substrates into cytolysin.17  
Owing to the lack of structural information on SLS, inferences about the regiospecificity 
and chemospecificity of the biosynthetic machinery must be based on the cytolytic activity of 
site-directed mutants. As expected, some residues of SagA were critical for the cytolytic activity, 
as mutation to alanine abolished activity.17 Replacement of a cysteine for a serine or vice versa at 
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a critical location resulted in slightly reduced cytolytic activity in vitro and in vivo.17 Intriguingly, 
prolines were also tolerated at such positions. The diminished activity suggested that 
heterocycles were likely present and played mostly a structural role, but given that the unnatural 
heterocycle decreased the cytolytic potency, electronic contributions cannot be ruled out.  
 
1.5 Thiopeptides: Posttranslational Modification Taken to the Extreme 
 The thiopeptides, defined by a central (tetrahydro)pyridine ring and at least one thiazole 
substituent (e.g. thiostrepton, Figure 1.1),3 were first discovered in 1948.51 Although the 
thiopeptides have a diverse array of functions, the most well known activity is to inhibit protein 
synthesis by interacting with the 50S ribosomal subunit or elongation factor Tu.3 Early feeding 
experiments using labeled amino acids demonstrated that these highly modified natural products 
are amino acid derived.3, 52 However, for over half a century, the biosynthetic pathway to this 
class of natural products remained elusive until four independent research labs reported the 
biosynthetic genes responsible for several thiopeptides within the span of a few months.53-56 
These initial studies have lead to a number of other discoveries for various thiopeptide 
biosynthetic gene clusters.57-61 Thiopeptides feature an extraordinary array of posttranslational 
modifications. Thiostrepton, for example, contains four thiazoles, a thiazoline, a 
dehydrobutyrine, three dehydroalanines, a quinaldic acid moiety, a tetrahydropyridine ring, a 
dihydroxylated isoleucine, and a carboxy amide (Figure 1.1).56  
It was hypothesized that two dehydroalanines underwent a [4+2] cycloaddition to 
produce the central 6-membered ring found in all thiopeptides, which was later supported by 
feeding experiments.52, 62 The “hetero-Diels-Alderase” responsible for this remarkable 
transformation was recently identified (TclM in thiocillin biosynthesis), which confirmed the 
original dehydroalanine hypothesis.63 Other enzymes involved in the ancillary posttranslational 
modifications have also been elucidated through genetic and biochemical studies.53, 57, 64  
Although thiopeptide biosynthesis is a fascinating example of chemical and genetic 
complexity, the use of these molecules in clinical medicine has been plagued by poor water 
solubility.28 In an effort to increase water solubility, and thus bioavailability, initial studies to 
determine the structure-activity relationship have been conducted using the thiostrepton and 
thiocillin biosynthetic frameworks.65-67 Introduction of a fosmid that contained the thiostrepton 
biosynthetic cluster into a precursor peptide deficient strain of Streptomyces laurentii 
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(thiostrepton producer) allowed genetic manipulation of the precursor peptide.65 Alanines 2 and 4 
(numbered N-terminus to C-terminus, Figure 1.1) in thiostrepton were permissive toward 
mutation.65 A parallel study with the thiocillin core peptide demonstrated that some positions  
were tolerant to substitution, while mutation to other positions either attenuated or abolished 
activity.66, 67 Notably threonine-3 is the only unmodified residue in thiocillin, and mutation of this 
position to serine resulted in a moderate loss of antibiotic activity (~50%).67 Attempts to increase 
the water solubility by incorporating charged residues into the more tolerant positions 
dramatically decreased antibiotic activity.66 Thus, the quest to engineer more bioavailable 
thiopeptide analogs continues. 
 
1.6 Emerging TOMMs 
 The aforementioned TOMMs only cover about half of the currently known landscape 
occupied by this natural product class, as illustrated in Figure 1.3. Some light was recently shed 
on a subset of uncharacterized TOMMs with the discovery of two new families of precursor 
peptides that share two traits: uncharacteristically long leader peptides that are homologous to 
known proteins and hypervariable C-terminal core regions.16 One family of these precursor 
peptides shares homology with the alpha subunit of nitrile hydratase.16 These nitrile hydratase-
related leader peptides (NHLPs) are present in a diverse set of organisms, with a distinct lineage 
being present in the Burkholderia order. These peptides have been subjected to natural 
combinatorial biosynthesis, as demonstrated by paralogous duplication within many genomes 
and peptides with hypervariable C-termini.14, 16 Thus, multiple NHLPs are predicted to be 
biosynthesized by a single organism. This is exemplified by 12 NHLPs found in Pelotomaculum 
thermopropionicum SI.16 The second family of recently discovered precursor peptides has 
homology to the Nif11 protein family, which are found in nitrogen-fixing bacteria but have 
unknown function. In many cases, the TOMM biosynthetic machinery is not present in the 
genomes with Nif11-related precursor peptides and is replaced with lanthionine biosynthetic 
machinery. Numerous Nif11-like peptides from Prochlorococcus marinus have been 
experimentally validated to produce mature lantipeptides. In this non-TOMM system, one 
bifunctional LanM enzyme was shown to install (methyl)lanthionine rings on 17 different 
substrates but likely modifies all 29 genetically encoded substrates.68 Catalytic promiscuity 
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allows bacteria with compact genomes to produce an array of secondary metabolites with 
minimal increase in genome size.68 
 Another recently characterized TOMM, plantazolicin, from the plant growth-promoting 
bacterium, Bacillus amyloliquefaciens FZB42, exhibits antibacterial properties towards select 
gram-positive bacteria through an unknown mechanism.69 The structure of this natural product 
has yet to be established, but deletion studies have indicated that the compound is extensively 
posttranslationally modified.69 
  
 
Figure 1.3 TOMM's family tree. A phylogenetic analysis of the global TOMM family 
constructed using the amino acid sequence of the docking protein.  For docking proteins that are 
naturally fused to the cyclodehydratase, only the predicted docking protein domain was used.  
The phyla represented are listed for each half of the tree. Cladal annotations for reported families 
are given whenever possible and are color-coded. The data for the phylogenetic analysis were 
collected and analyzed using the Biopython library and MEGA4 software, respectively.43, 70 
 
1.7 Evolutionary Aspects of TOMMs 
 TOMMs can be diversified using multiple mechanisms (Figure 1.4). In regard to 
precursor diversification, the bipartite character of TOMM precursor peptides allows the TOMM 
biosynthetic enzymes to be both specific for substrate binding yet promiscuous in terms of 
installing posttranslational modifications. This allows an organism to assess the functional 
ramification of core peptide mutations, of which some may yield increased target potency or a 
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new target altogether (Figure 1.4). Nature has iteratively performed this operation over the eons 
to arrive at numerous privileged scaffolds. Much like medicinal chemists would diversify a 
promising lead compound, TOMM producers can obtain/evolve genes encoding enzymes that 
further elaborate existing TOMMs. An example of this is the “hetero-Diels-Alderase” of the 
thiopeptides. Here, Nature took a thiopeptide ancestor, likely resembling goadsporin (Figure 
1.1),71 and developed an enzyme that could join two dehydroalanines into a tetrahydropyridine 
ring (Figure 1.4). This quantum leap in biosynthetic capacity transformed the mode of action of 
the resultant molecule into a potent inhibitor of protein synthesis. Thus, a powerful weapon for 
niche competition was born, which is now disseminated in many genera of soil bacteria.3 It is 
probable that the scope of functionality for this natural product family has not yet been fully 
realized.  
 
 
Figure 1.4 Genetically encoded medicinal chemistry. Shown is an ancestral TOMM produced 
by a basic biosynthetic cluster consisting of a precursor peptide (A, black arrow), dehydrogenase 
(B, yellow arrow), cyclodehydratase (C, green arrow), and docking protein (D, blue arrow). Core 
peptide mutations (black and white striped arrow) and/or altered 
regiospecificity/chemospecificity of the biosynthetic machinery provide one route to diversify 
the ancestral TOMM. This not only changes the number and position of cyclized residues, but 
also can alter the physicochemical properties of the final product. Another method to structurally 
diversify the TOMM involves the acquisition of ancillary enzymes (X and Y) that carryout 
additional posttranslational modifications (orange hexagon and red triangle) to diversify the 
TOMM scaffold. This can result in an entirely new function, relative to the ancestral TOMM.  
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1.8 Summary and Outlook 
By sifting through publicly available genome databases, bioinformatics-based approaches 
have identified over 300 TOMM biosynthetic gene clusters. The function of many of these can 
be inferred based on close phylogenetic relationships to characterized TOMMs (Figure 1.3), We 
refer to this process as bioinformatics-guided chemotyping. However, there is a vast area of 
TOMM chemical/genetic space that awaits structural and functional characterization, and will 
continue to be an area of growth. This unexplored area has been growing linearly with efforts in 
microbial genome sequencing, suggesting that new TOMM subfamilies will continue to be 
uncovered. 
 Future studies, from both chemical and biological perspectives, will provide a more 
complete knowledge of the enzymes responsible for the peptide modifications, as well as the 
order and specificity in which they occur. Additionally, the role of the docking protein in 
orchestrating TOMM biosynthesis remains unclear. Future efforts should focus on the docking 
protein's role in heterocycle formation. The biochemical knowledge of critical and ancillary 
enzymes will allow for the rational design and production of artificial TOMMs. Other future 
studies will focus on the production and screening of combinatorial libraries for increased 
potency and novel modes of action. Overall, the TOMM natural product family is a prolific 
source of chemical and functional diversity, and represents one strategy Nature adopted to 
synthesize complex natural products from a ribosomal template. 
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Chapter 2: Selectivity, Directionality, and Promiscuity in Peptide Processing from a 
Bacillus sp. Al Hakam Cyclodehydratase 
 
Reprinted with permission from Melby, J. O., Dunbar, K. L., Trinh, N. Q., and Mitchell, D. A. 
(2012) Selectivity, directionality, and promiscuity in peptide processing from a Bacillus sp. Al 
Hakam cyclodehydratase, J Am Chem Soc 134, 5309-5316. Copyright 2012 American Chemical 
Society. 
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Abstract 
 The thiazole/oxazole-modified microcins (TOMMs) represent a burgeoning class of 
ribosomal natural products decorated with thiazoles and (methyl)oxazoles originating from 
cysteines, serines and threonines. The ribosomal nature of TOMMs allows for the generation of 
derivative products from mutations in the amino acid sequence of the precursor peptide, which 
ultimately manifest in differing structures and sometimes biological functions. Employing a 
TOMM system for the purpose of creating new structures and functions via combinatorial 
biosynthesis requires processing machinery that can tolerate highly variable substrates. In this 
study, TOMM enzymatic promiscuity was assessed using a currently uncharacterized cluster in 
Bacillus sp. Al Hakam that likely produces two TOMMs of unknown structure and function. As 
determined by Fourier transform tandem mass spectrometry (FT-MS/MS), azole rings were 
formed in both a regio- and chemoselective fashion. Cognate and non-cognate precursor peptides 
were modified in an overall C- to N-terminal directionality, which to date is unique among 
characterized ribosomal natural products. Studies focused on the inherent promiscuity of the 
biosynthetic machinery elucidated a modest bias for glycine at the preceding (-1) position and a 
remarkable flexibility in the following (+1) position, even allowing for the incorporation of 
charged amino acids and bisheterocyclization. Two unnatural substrates were utilized as the 
conclusive test of substrate flexibility, of which both were processed in a predictable fashion. A 
greater understanding of substrate processing and enzymatic tolerance towards unnatural 
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substrates will prove beneficial when designing combinatorial libraries to screen for artificial 
TOMMs that exhibit desired activities. 
 
2.1 Introduction 
 The thiazole/oxazole-modified microcins (TOMMs) comprise a recently described class 
of posttranslationally modified peptide natural products whose thiazole and (methyl)oxazole 
heterocycles derive from cysteine, serine and threonine residues.1 Characterized members of this 
natural product family exhibit a myriad of functions including, but not limited to antibacterial 
compounds, antitumor agents, and cytolytic virulence factors.2-4 Despite the initial discovery of 
the requisite heterocycle forming enzymes approximately 15 years ago, biochemical 
characterization of the TOMM enzymatic machinery has been limited to the microcin B17, 
thiazole/oxazole-containing cyanobactin, and streptolysin S (SLS) synthetases.3, 5, 6 Previous 
efforts to elucidate the complex underpinnings of substrate processing have been stymied due to 
poor protein stability, solubility, and difficulties in monitoring heterocycle formation.7, 8 The 
discovery of a novel TOMM cluster in Bacillus sp. Al Hakam (Balh) with more ideal physical-
chemical properties made it possible to further explore the factors governing substrate processing 
with potential implications towards artificial TOMM engineering via a combinatorial 
biosynthetic approach.  
 Although TOMMs can display a wide range of posttranslational modifications, their 
defining features are thiazole and (methyl)oxazole heterocycles. These “azole” rings are installed 
over two enzymatic steps. First, a complex of the TOMM cyclodehydratase (C-protein) and the 
docking protein (D-protein) catalyzes the cyclodehydration of cysteine, serine, and threonine 
residues to azoline heterocycles (Figure 2.1). 3, 5, 7, 9 The collaborative enzymatic effort of the C- 
and D-proteins is genetically illustrated in roughly half of all identified TOMMs, where they are 
produced as a single polypeptide.1 The azoline rings in many cases undergo a subsequent 2-
electron oxidation to the azole heterocycle by the action of a flavin mononucleotide (FMN)-
dependent dehydrogenase (B-protein).7 Many TOMM clusters also contain ancillary tailoring 
enzymes, which add to the structural complexity of this class of natural products.1, 10 
As with the lantipeptides and other ribosomal peptide natural products, the N-terminal 
portion of the TOMM precursor peptide, referred to as the leader peptide (Figure 2.1), has been 
implicated in substrate recognition and appears to direct the precursor peptide to the biosynthetic 
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complex.11, 12 The C-terminal portion of the substrate, denoted as the core peptide, is extensively 
modified and converted into a bioactive natural product. Importantly, the primary amino acid 
sequence of the core peptide directly encodes the structure/function of the mature TOMM. Often 
the biological function of a previously uncharacterized TOMM can be accurately predicted based 
on similarity to characterized family members.1, 8 
 Early studies of microcin B17 identified and reconstituted the enzymes responsible for 
the installation of thiazole and oxazoles.5, 13 Later investigations formed the foundation for much 
of the current knowledge on the selectivity of thiazole/oxazole installation. A combination of 
cysteine alkylation and MS/MS analysis indicated an overall N- to C-terminal directionality of 
ring formation on the microcin B17 precursor peptide. However, the exact order of ring 
formation could never be established using MS/MS, as the thiazole and oxazole heterocycles 
suppressed fragmentation and prevented the precise localization of some intermediates.14 Further 
investigations concluded that the heterocycle-forming enzymes are both regio- and 
chemoselective.14-16 Walsh and coworkers also determined that mutating flanking residues around 
the first bisheterocycle site decreased the rate of heterocycle formation, and combined with its 
poor biophysical properties render the microcin B17 system a poor candidate for combinatorial 
engineering.7, 16  
The initial studies of microcin B17 processing have provided insights into substrate 
processing in additional TOMM clusters; two noteworthy examples are the thiazole/oxazole-
containing cyanobactins and SLS. The cyanobactins are macrocyclic ribosomal peptides 
produced by cyanobacteria, while SLS is a well-known virulence factor from Streptococcus 
pyogenes.3, 17 Studies conducted by Schmidt and coworkers demonstrated that heterocycle 
formation in the cyanobactins appeared to be regulated mainly by regioselective factors and that 
a high degree of flexibility existed regarding the cyclized residue and flanking residues (i.e. 
polar, hydrophobic, and charged).9 In contrast to the relatively well-characterized cyanobactins, 
the structure of SLS remains elusive, and as such the finer details of cyclization have not been 
determined. However, studies using non-cognate SLS substrates established the flexible nature 
of the biosynthetic machinery.18 Although these works have been instrumental in the expansion 
of our knowledge regarding TOMM biosynthesis, no previously characterized enzyme complex 
had the requisite in vitro characteristics for cell-free production of highly variable TOMMs. 
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 In search of a TOMM biosynthetic gene cluster ideally suited for detailed biochemical 
studies of substrate selectivity and promiscuity, genome mining revealed two clusters in the Balh 
genome, whose natural products remain structurally and functionally uncharacterized.19 The first, 
cluster 1, which is the focus of the current study, contained all the required biosynthetic genes in 
neighboring open reading frames and harbored two precursor peptides (BalhA1 and BalhA2, 
Figure 2.1). The natural BalhA1/A2 substrates address a variety of shortcomings that plagued in-
depth biochemical characterization of previously studied TOMMs. We predicted that the large 
number of polar amino acids in the precursor peptides would aid solubility and visualization of 
heterocycles by mass spectrometry. Moreover, the inclusion of tyrosine and tryptophan residues 
allow for facile UV-detection. Bioinformatic approaches have identified four closely related gene 
clusters (gene similarity, directionality, and order within the cluster) to Balh cluster 1, all within 
the Bacillus cereus group (Figure 2.2). The second TOMM cluster in Balh (cluster 2) is found in 
virtually all Bacillus cereus group members (Figure 2.3). Because of the attractiveness of the 
cluster 1 precursor peptides towards chromatography, mass spectrometry, and the relative ease of 
obtaining recombinant protein in good yield and purity, we employed this TOMM system to 
further probe substrate processing in the natural product family. This work highlights the 
robustness of the Bacillus sp. Al Hakam TOMM enzymes and lays the foundation for larger-
scale natural product engineering efforts.  
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Figure 2.1 Thiazole/oxazole formation and genetic organization of the TOMM from 
Bacillus sp. Al Hakam. A. ATP-dependent cyclodehydration of a peptidic cysteine or serine/ 
threonine results in the formation of a thiazoline or (methyl)oxazoline ring. These azoline 
heterocycles can be oxidized to the aromatic azole heterocycles through an FMN-dependent 
dehydrogenation. B. The first TOMM cluster in B. sp. Al Hakam consists of two precursor 
peptides (A1 and A2, black), a cyclodehydratase (C, green), docking protein (D, blue), 
dehydrogenase (B, yellow), an ABC transporter (red), and two hypothetical proteins (grey and 
white). C. Sequences of precursor peptides used in this study. The blue/orange letters signify 
heterocyclizable residues. The scrambled portion of BalhA1-Scramble is underlined. The orange 
residues of the chimera substrates were predicted to be cyclized by the Balh thiazole/oxazole 
synthetase. 
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Figure 2.2 TOMM clusters closely related to cluster 1 from Balh. A. The TOMM clusters 
were aligned with the Balh TOMM cluster 1. Each arrow represents an open reading frame. 
Predicted functions of the genes are described in the legend. B. Alignment of the precursor 
peptides from each related cluster. Heterocyclizable residues are shown in blue. 
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Figure 2.3 Genetic organization of the Balh TOMM cluster 2 and related clusters. This 
biosynthetic gene cluster is extensively propagated in the Bacillus cereus group. A. An open 
reading frame diagram of cluster 2 from Balh. B. A table of all currently sequenced Bacillus 
cereus group members (88 total) and the gene locus of the Balh2CD homolog (if present). All 
but two organisms have a readily identifiable similar cluster (86 total organisms). Encoded 
elsewhere on the genome exists a probable fourth TOMM precursor peptide, which was 
identified by virtue of a homolog being proximal to the synthetase genes in B. licheniformis.20   
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2.2 In vitro Reconstitution of the Enzymatic Activity of the Balh TOMM Enzymes 
 Both substrates and the requisite enzymes in the Balh TOMM cluster 1 were cloned, 
overexpressed in E. coli, and purified as TEV protease cleavable fusions to maltose binding 
protein (MBP). Although each protein was isolated in good yield and purity, the dehydrogenase 
(BalhB) purified without the necessary FMN cofactor bound, and varied attempts to increase 
FMN loading were met with limited success. Similar challenges have been solved in other 
TOMM systems through the use of a surrogate dehydrogenase from a similar TOMM cluster.8 
Therefore, a highly similar dehydrogenase (78% identity/94% similarity) from B. cereus 
172560W (BcerB, Figure 2.2), which purified with the necessary FMN cofactor bound after 
heterologous expression in E. coli, was used for in vitro assays with BalhC and BalhD. A 
synthetase reaction, containing the BalhA1 substrate, BalhC, BalhD, and the non-cognate 
(surrogate) dehydrogenase, BcerB, was digested with trypsin and analyzed using LC-FTMS. The 
resulting spectra clearly showed the presence of five azole heterocycles installed on the BalhA1 
precursor peptide (Figure 2.4; -100 Da). To determine if the two heterocyclizable residues at the 
extreme C-terminus of BalhA1 (not present in the tryptic fragment) were modified, an analogous 
experiment replacing trypsin with TEV protease was performed. Here, the full-length precursor 
peptide was analyzed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) MS and found to contain five azole heterocycles, which indicated the extreme C-terminus 
of BalhA1 was unmodified under the conditions employed (Figure 2.5). Omission of the 
dehydrogenase resulted in a mass loss consistent with the formation of five azoline heterocycles, 
indicating that cyclodehydration occurred in the absence of the dehydrogenase.21 
 Further time course studies of azole formation demonstrated the accumulation of multiple 
intermediates (Figure 2.6). As such, the Balh thiazole/oxazole synthetase processed substrate in a 
distributive fashion, reminiscent of trunkamide and microcin B17 processing.14, 22 It is worth 
noting that the distributive nature of TruD (trunkamide cyclodehydratase) was only seen when an 
inadequate amount of ATP was supplied.22 Through LC-FT-MS/MS studies, the five azole 
heterocycles installed upon BalhA1 were localized to five cysteines (C28, 31, 34, 40 and 45; 
Figure 2.4), as determined by the loss of mass and fragmentation pattern surrounding the 
modified amino acids.14, 15 The discriminating activity towards particular cysteines posed several 
questions about residue tolerance and prompted a more thorough investigation into the chemo- 
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and regioselectivity of the Balh thiazole/oxazole synthetase, as well as the effects of altering the 
local environment. 
 
Figure 2.4 In vitro azole synthesis on BalhA1. A. A tryptic digestion of a synthetase reaction 
composed of BalhA1 treated with BcerB/BalhCD produced tryptic fragments with four and five 
azole heterocycles. The 4+ charge state is shown and the number next to the peak corresponds to 
the number of heterocycles. Experimental and theoretical monoisotopic masses are given for the 
five azole ring species. B. MS/MS of the five azole tryptic fragment of BalhA1 shown in A. The 
b+ and y+ ions are labeled blue and orange, respectively. The observed fragmentation was 
annotated based on the residue number within the tryptic fragment. The five azole heterocycles 
were localized to C28, C31, C34, C40 and C45 (stars). 
 
	  	   29 
 
Figure 2.5 MALDI-TOF MS of full length BalhA1. A synthetase reaction containing MBP-
BalhA1, MBP-BcerB, MBP-BalhC, and MBP-BalhD was allowed to react for 16 h, and then 
cleaved with TEV protease (red spectrum). The black spectrum is the negative control that 
lacked the addition of BCD proteins. The +1 charge state is shown. A loss of 100 Da is 
indicative of 5 azole rings (5 x -20 Da). In accordance with Figure 2, these 5 azole heterocycles 
were located on the tryptic fragment. The asterisk denotes a laser-induced artifact. 
 
Figure 2.6 Distributive nature of Balh TOMM synthetase. MBP-BalhA1, MBP-BcerB, MBP-
BalhC, and MBP-BalhD were allowed to react for 45 minutes before trypsin digestion and 
subsequent LC-FTMS analysis. Multiple intermediates were detected, indicating that the 
enzyme-substrate complex was dissociating between catalytic events. If the enzymes were 
processive, the intermediate ring species would not build up and only the unmodified and fully 
modified species would be observed. 
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2.3 Chemoselectivity of the Cyclodehydration Reaction 
 The observation of solely thiazole rings after enzymatic treatment led to the hypothesis 
that the enzymes were exceptionally chemoselective for cysteine, which is in contrast to many 
other characterized TOMMs.23-27 Given the distributive nature of substrate handling, multiple 
intermediates accumulated at non-equivalent rates, rendering a detailed kinetic analysis 
exceedingly complicated. To circumvent this complexity, a gene encoding a non-cyclizable (NC) 
version of BalhA1 was synthesized in which the cysteines/serines and threonines were changed 
to alanines and valines, respectively (Table 2.1). Because TOMM heterocyclization has been 
previously shown to be directly coupled to ATP hydrolysis and even occurred in a near 
stoichiometric fashion in the case of TruD, substrate processing rates were monitored using an 
assay specific for phosphate detection.22, 28, 29  
 To determine if the BcerB/BalhCD enzymes were indeed capable of forming 
(methyl)oxazoles, point mutants of the NC substrate analog containing cysteine, serine, and 
threonine were generated at three of the five heterocyclized sites (31, 40 and 45). As predicted 
from inherent nucleophilicity, cysteine was processed most rapidly at all three positions (Tables 
2.2 and 2.3).15 Although reactions with the native BalhA1 substrate suggested that 
serines/threonines were not able to be cyclized, placement of both serine and threonine at 
position 40 also resulted in ATP hydrolysis (Table 2.2), and by inference, heterocycle formation. 
Given that the microcin B17 biosynthetic enzymes were shown to process serine about 100- to 
1000-fold slower than cysteine,15 it is notable that the Balh TOMM biosynthetic enzymes only 
have a 30-fold slower processing rate for serine compared to cysteine at position 40. As a 
control, Michaelis-Menten kinetic parameters were obtained for wild type substrate and the 
amenable mutants (Table 2.2). The decreased processing efficiency could not be attributed to a 
decreased apparent Km, and indicated the rates measured were true reflections of processing 
efficiencies. Preliminary efforts to directly confirm that ATP hydrolysis resulted in 
(methyl)oxazoline formation were not fruitful because BcerB proved unable to oxidize the 
azoline. Such heterocycles hydrolytically ring open, yielding the original amino acid, under 
standard LC-based purifications at lower pH values. An alternative approach was developed that 
involved TEV protease cleavage of the peptide from MBP and organic solvent-based 
precipitation of all large proteins (MBP and the biosynthetic enzymes). Under the conditions 
employed, only smaller polypeptides remain soluble, thus allowing for relatively clean MS 
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samples without the need for LC. Our MS methods allowed for visualization and localization of 
the dehydration to position 40 (NC-A40T and NC-A40S, Figures 2.7 and 2.8 respectively). 
These experiments demonstrated that the enzymatic machinery exhibited moderate 
chemoselectivity for cysteine; however, our data did not reconcile the lack of (methyl)oxazoline 
rings in the native substrate, as serine and threonine were accepted as substrates and are found in 
the core peptide of BalhA1. Thus, we hypothesized that the synthetase was regioselective for the 
specific positions where cyclization was confirmed in the native substrate.  
 
 
Table 2.1 Select non-cyclizable (NC) and BalhA1 mutant sequences. Amino acid sequence of 
various NC mutants aligned with BalhA1 and NC. Residue(s) in red indicate the site of point 
mutation(s), relative to NC. Residues in blue indicate inserted sequences. 
  
Precursor Peptide Amino Acid Sequence 
BalhA1 MEQKKILDIKLTETGKINYAHKPDDSGCAGCMGCAGGTGCAGTGCIGQGVWKKCSGK 
NC MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVGAAGVGAIGQGVWKKAAGK 
NC-A28C MEQKKILDIKLTETGKINYAHKPDDAGCAGAMGAAGGVGAAGVGAIGQGVWKKAAGK 
NC-A31C MEQKKILDIKLTETGKINYAHKPDDAGAAGCMGAAGGVGAAGVGAIGQGVWKKAAGK 
NC-A34C MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGCAGGVGAAGVGAIGQGVWKKAAGK 
NC-A40C MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVGCAGVGAIGQGVWKKAAGK 
NC-A45C MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVGAAGVGCIGQGVWKKAAGK 
NC-A40S MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVGSAGVGAIGQGVWKKAAGK 
NC-A40T MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVGTAGVGAIGQGVWKKAAGK 
NC-G39A/A40C MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVACAGVGAIGQGVWKKAAGK 
NC-G39D/A40C MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVDCAGVGAIGQGVWKKAAGK 
NC-A40C/A41G MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVGCGGVGAIGQGVWKKAAGK 
NC-A40C/A41D MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVGCDGVGAIGQGVWKKAAGK 
NC-A40C/G42I MEQKKILDIKLTETGKINYAHKPDDAGAAGAMGAAGGVGCAIVGAIGQGVWKKAAGK 
BalhA1 G47* MEQKKILDIKLTETGKINYAHKPDDSGCAGCMGCAGGTGCAGTGCI 
BalhA1 C54* MEQKKILDIKLTETGKINYAHKPDDSGCAGCMGCAGGTGCAGTGCIGQGVWKK 
BalhA1 GAG Ins MEQKKILDIKLTETGKINYAHKPDDGAGSGCAGCMGCAGGTGCAGTGCIGQGVWKKCSGK 
BalhA1 GAGGAG Ins MEQKKILDIKLTETGKINYAHKPDDGAGGAGSGCAGCMGCAGGTGCAGTGCIGQGVWKKCSGK 
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Table 2.2 Chemoselectivity of the Balh cyclodehydratase. a % WT = (Substrate Vo / WT Vo) x 
100 b Apparent Km c Not determined. 
 
 
 
 
Table 2.3 Selected non-cyclizable mutants processing rates measure using the purine 
nucleoside phosphorylase assay. n.d. = not detectable. a % WT = (Substrate Vo / WT Vo) x 100 
  
Substrate Vo (μM Pi min-1) % WTa Km, µM b kobs, min-1  kobs/Km, M-1 s-1 
WT 20.2 ± 0.7 100 16 ± 2 12.9 ±0.4 (13 ± 2) x 103 
NC-A40C 18 ± 1 88 15.3 ± 0.9 10.8 ±0.2 (11.8 ± 0.7) x 103 
NC-A40S 0.63 ± 0.09 3.1 n.d.c n.d. c n.d. c 
NC-A40T 3.2 ± 0.1 16 16 ± 2 1.38 ±0.06 (1.4 ± 0.2) x 103 
 
Substrate Vo (µM Pi min-1) % WTa 
NC-G30A/A31C 0.09 ± 0.08 0.5 
NC-A31S 0.12 ± 0.02 0.6 
NC-A31T 0.04 ± 0.05 0.2 
NC-A31C/M32G 0.01 ± 0.04 0.05 
NC-A31C/A40P 4.7 ± 0.2 23 
NC-A31S/A40P 0.02 ± 0.02 0.1 
NC-A31T/A40P 0.07 ± 0.05 0.3 
NC-A34C/A40P 2.7 ± 0.5 13 
NC-G39K/A40C n.d. n.d. 
NC-G39P/A40C n.d. n.d. 
NC-A40C/A41K 9 ± 2 40 
NC-A40C/A41P n.d. n.d. 
NC-A45S n.d. n.d. 
NC-A45T 0.2 ± 0.06 1 
NC-A45C/I46G 0.09 ± 0.05 0.4 
NC-A40P/A45C 2.6 ± 0.4 13 
BalhA1-Scramble 1.6 ± 0.7 7.9 
BalhA1-McbA 0.42 ± 0.05 2.1 
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Figure 2.7 ESI-MS of NC-A40T before and after treatment with BalhCD. The mass loss in 
the 5+, 6+ and 7+ charge states are indicative of an oxazoline ring (-18 Da). MS/MS was used to 
localize the mass loss to the threonine (starred). The b- and y-ions observed from MS/MS are 
labeled on the amino acid sequence, and red hash marks indicate the -18 Da mass loss was 
observed on that particular fragment. The hyphen represents the remaining N-terminal amino 
acid sequence (not shown).	  
 
Figure 2.8 ESI-MS of NC-A40S before and after treatment with BalhCD. The mass loss in 
the 5+, 6+ and 7+ charge states are indicative of an oxazoline ring (-18 Da). MS/MS was used to 
localize the mass loss to the serine (starred). The b- and y-ions observed from MS/MS are 
labeled on the amino acid sequence, and red hash marks indicate the -18 Da mass loss was 
observed on that particular fragment. The hyphen represents the remaining N-terminal amino 
acid sequence (not shown).	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2.4 Regioselectivity of the Cyclodehydration Reaction 
To probe the regioselectivity of azole formation, a series of alanine to cysteine point 
mutations were introduced on the non-cyclizable (NC) substrate at the naturally occurring 
cyclized positions in BalhA1. Based on literature precedent for the N- to C-terminal 
directionality for ribosomally synthesized peptidic natural products, the most N-terminal mutant 
(NC-A28C) was expected to have the fastest rate of cyclodehydration.14, 30-32 Surprisingly, NC-
A40C was the fastest by a factor of 18 (Table 2.4). All other single cysteine substrates (NC-
A28C, -A31C, -A34C, -A45C) had significantly slower rates of ATP hydrolysis. From these 
data, we surmised that the rate of ring formation at positions other than 40 might be enhanced 
upon conformational restriction at position 40. For example, synthetase reactions containing 
BalhA1 (50 µM), BcerB (5 µM), BalhC (1 µM), and BalhD (1 µM) reach completion within 6 
hours. Without taking into account C40 or the rate decrease as a function of substrate 
concentration, the reaction would take over 16 hours if there were no rate enhancement after 
heterocycle installation. Such synergy between heterocycle sites has been previously reported in 
microcin B17 processing.33 We hypothesized that installing a proline, which has previously been 
shown to functionally substitute for thiazoles and oxazoles, at position 40 would mimic the first 
thiazole produced and enhance the processing rate of downstream residues.18 This rate 
enhancement was most notable with NC-A31C/A40P, which was nearly 6-fold faster than NC-
A31C and also suggested that C31 may be the second thiazole (Tables 2.3 and 2.5). Even though 
conformational restriction at position 40 enhanced ring formation elsewhere, it is important from 
a combinatorial engineering perspective that cyclization at position 40 was not strictly required 
for processing at secondary sites.  
 
 
Table 2.4 Regioselectivity of the Balh cyclodehydratase. a % WT = (Substrate Vo / WT Vo) x 
100 
  
Substrate Vo (μM Pi min-1)  % WTa 
NC-A28C 1.0 ± 0.1 4.7 
NC-A31C 0.81 ± 0.09 4.0 
NC-A34C 0.5 ± 0.2 2 
NC-A40C 18 ± 1 88 
NC-A45C 0.80 ± 0.09 4.0 
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Table 2.5 Effect of flanking residues on the rate of cyclodehydration. a % WT = (Substrate Vo 
/ WT Vo) x 100 
 
2.5 Order of Ring Formation 
The NC substrate analog data suggested C40 and C31 would be the first and second azole 
heterocycles, respectively, and warranted a more complete investigation into the order of ring 
formation. The isolation of a one ring species and subsequent MS/MS analysis allowed for the 
localization of the first thiazole (Figure 2.9 and Scheme 2.1). The 20 Da mass loss in the MS/MS 
spectra of single ring species was only detected in the b-ion series starting at b26++ and the y-ion 
series starting at y14+. Moreover, fragmentation was not observed at the amide bonds directly 
adjacent to C40, which is a well-known behavior for this type of chemical species.14, 15 Together, 
these observations were consistent with the kinetic results obtained with the aforementioned NC 
substrates and unequivocally localized the first heterocycle to C40 (Scheme 2.1). For the two 
ring species, ions that indicated C31 and C34 as the second heterocycle appeared with equal 
intensity (b16++ and y20+), suggesting a divergent biosynthetic pathway. However, reconvergence 
was immediate, as fragmentation of the three ring species produced fragment ions indicative of 
thiazoles only at C31, C34 and C40. The site of the fourth ring and fifth ring were C45 and C28, 
respectively. These data demonstrated that the Balh thiazole/oxazole synthetase modified 
BalhA1 in a unique C- to N-terminal overall direction, although not strictly.  
To determine if the directionality of thiazole synthesis was also observed with other 
closely related biosynthetic clusters or an artifact of using the non-cognate dehydrogenase, the 
cyclodehydratase (BcerC) and docking protein (BcerD) from B. cereus 172560W were also 
cloned and purified. Combined with BcerB, this represented a cognate biosynthetic system for 
thiazole/oxazole synthesis and could be used to validate the experiments conducted with the Balh 
system. BcerBCD processed BalhA1 in an identical fashion as that observed with BcerB, BalhC 
Substrate Vo (μM Pi min-1)  % WTa 
NC-G39A/A40C 0.67 ± 0.05 3.3 
NC-G39D/A40C 0.1 ± 0.1 0.3 
NC-A40C/A41G 6.6 ± 0.1 33 
NC-A40C/A41D 17 ± 3 82 
NC-A40C/G42I 13.1 ± 0.3 64.8 
NC-A31C/A40P 4.7 ± 0.2 23.3 
 
	  	   36 
and BalhD, with the minor exception of cyclizing C31 exclusively as the second thiazole (Figure 
2.10).  
 
Figure 2.9 MS/MS fragmentation of BalhA1 reaction intermediates. Data collected from 
synthetase reactions of MBP-BalhA1 treated with MBP-tagged BcerB/BalhCD. The fragment 
ions observed for various ring intermediates are denoted by the b+ and y+ ion symbols. The 
number at the leftmost edge of the figure indicates the ring state. Cysteines are numbered based 
on the sequence of full length BalhA1. Black = 0 rings. Red = 1 ring. Green = 2 rings. Brown = 3 
rings. Grey = 4 rings. Light blue = 5 rings. The stars signify heterocycle locations. The two ring 
species showed an equal abundance of C31 and C34 as the second heterocycle, and the ions 
indicative of this are denoted by the asterisk. 
 
 
 
Scheme 2.1 Order of thiazole formation on BalhA1  
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Figure 2.10 Thiazole ring order of BalhA1 with BcerBCD. Data were collected from 
synthetase reactions of MBP-BalhA1 treated with MBP-BcerBCD. The fragment ions observed 
for various ring intermediates are denoted by the b+ and y+ ion symbols. The number at the 
leftmost edge of the figure indicates the ring state. Cysteines are labeled based on the full length 
BalhA1. Black = 0 rings. Red = 1 ring. Green = 2 rings. Brown = 3 rings. Grey = 4 rings. Light 
blue = 5 rings. The stars signify heterocycle locations. 
 
 
2.6 Importance of Flanking Residues on the Cyclodehydration Reaction 
An analysis of the local sequence around the cyclized residues in BalhA1, as well as 
predicted cyclized residues in the other closely related homologs, revealed three generally 
conserved trends (Figure 2.11). i. Glycine nearly always preceded the putatively cyclized 
cysteine (-1 position). ii. Conversely, glycine rarely occurred directly following the putatively 
cyclized cysteine (+1), which was largely populated by hydrophobic amino acids. iii. A 
practically invariant glycine was found in the +2 position. As before, we utilized the NC 
substrate analog as a platform to ascertain the level of tolerance that existed at each of these 
positions. The necessity of the conserved glycine in the -1 position was first assessed. A 
preceding glycine could conceivably enhance the rate of cyclization because of the decreased 
steric bulk at Cα, allowing for greater Ramachandran space to be sampled.5 In congruence with 
this hypothesis, the replacement of glycine with alanine, aspartic acid, or lysine in the -1 position 
decreased the rate of ATP consumption (Tables 2.3 and 2.5). This result was reminiscent of 
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studies performed on microcin B17 and SLS processing. The microcin B17 synthetase did not 
tolerate substitutions in the -1 position, in relation to the first bisheterocycle site.16 Moreover, 
only two azole heterocycles have been detected and localized by mass spectrometry on SagA 
(precursor peptide of SLS), both of which harbor glycine in the -1 positions.8 While the presence 
of a preceding glycine appears to accelerate heterocycle formation, it is by no means a stringent 
requirement for heterocyclization as thiazole/oxazole-containing-cyanobactins, thiopeptides, and 
other TOMMs often lack glycines preceding the azole/azoline heterocycles.23-27 In these systems, 
we speculate that the presence of a -1 glycine may abolish or diminish biological activity, forcing 
the evolution of TOMM enzymes to accept residues with restricted Ramachandran space.  
Modulating the steric bulk in the +1 position had a lesser effect on the rate of ATP 
consumption, and this position even tolerated charged residues (Tables 2.3 and 2.5). The only 
amino acid tested that was not tolerated in the +1 position was proline (Table 2.3). From a 
combinatorial biosynthesis perspective, flexibility towards charged and hydrophobic residues 
could be very beneficial when tuning bioavailability/water solubility and membrane 
permeability. The microcin B17 biosynthetic enzymes did not display such flexibility in the +1 
position.16 The +2 position (glycine) also tolerated substitution (Tables 2.3 and 2.5). It is 
important to note that the +2 glycine may be an artifact of the precursor peptide sequence. In 
many cases, this glycine precedes another cyclized cysteine or heterocyclizable residue, which 
may evade in vitro processing but be a bona fide site of heterocyclization in vivo. However, we 
cannot rule out the possibility that the conserved +2 glycine could also be crucial for biological 
activity, which would also explain its conserved nature and minimal effect on heterocyclization 
rate.  
 
Figure 2.11 WebLogo of residues surrounding a heterocyclized site. The surrounding 
residues of the cysteines (30 total) shown in Figure 2.2 that align with the cyclized cysteines in 
BalhA1 were used to make this WebLogo.34 This logo was used to guide the studies probing the 
importance of the local environment for efficient processing. 
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2.7 Heterocyclization of BalhA2 and BcerA 
As previously mentioned, the Balh TOMM cluster has two precursor peptides (Figure 
2.1); therefore, we sought to characterize the processing of the second peptide, BalhA2. 
Compared to BalhA1, the BalhA2 substrate had a similar apparent Km (17 ± 2 µM) but a reduced 
kobs (4.4 ± 0.2 min-1). An alignment of these two precursor peptides showed that C28, C31, T34 
and C37 of BalhA2 aligned with cysteines that are cyclized in BalhA1 (Figure 2.12). Many of 
these positions do not contain the favored -1 glycine, likely resulting in the reduced kobs for 
BalhA2. A synthetase reaction of BalhA2 with BcerB, BalhC, and BalhD resulted in three azole 
heterocycles and 1 azoline heterocycle (Figure 2.13). Upon trypsin digestion and LC-FTMS 
analysis, three azole heterocycles remained and were localized to C28, C31, and C37 (Figures 
2.14 and 2.15). The lone azoline ring eluded exact localization; however, the MS/MS 
fragmentation narrowed down the azoline location to T34, T35, or S36 (Figure 2.13). The 
presence of a -1 glycine at T34 and its alignment with C34 of BalhA1 left T34 as our predicted 
site for the azoline heterocycle. The order of azole formation on BalhA2 was determined to be 
strictly C- to N-directional using BcerB/BalhC/BalhD and BcerBCD (Figures 2.16 and 2.17). 
The substrate from the B. cereus 172560W cluster (BcerA) was processed in a highly similar and 
thus predictable fashion (Figures 2.18-2.20). Taken together with the BalhA1 results, these data 
represent, to the best of our knowledge, a heretofore-unreported processing direction for a 
ribosomally synthesized natural product.14, 30-32  
 
 
Figure 2.12 Alignment of BalhA1 and BalhA2. The cysteines in BalhA2 that are cyclized are 
underlined and in red. The numbers above and below the alignment correspond to the position 
within the BalhA1 and BalhA2 sequence, respectively. 
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Figure 2.13 ESI-MS of BalhA2 after treatment with BcerB/BalhCD. The 5+ charge state is 
shown. The monoisotopic mass of the green peak is shown and is indicative of 3 azole rings and 
an azoline ring. The light blue peak corresponds with a 3 azole ring species, and the brown peak 
corresponds to the 2 azole rings and 1 azoline ring species. MS/MS of the green peak produced 
the fragmentation seen below, which localized the azoline ring to three residues (TTS). The b- 
and y-ions observed from MS/MS are labeled on the amino acid sequence. Red = 2 azole rings. 
Grey = 1 azole and 1 azoline ring. Blue = 2 azole and 1 azoline ring. Green = three azole and 1 
azoline ring. The stars signify definititive heterocycle locations. 
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Figure 2.14 LC-FTMS analysis of a BalhA2 synthetase reaction. A tryptic digestion of a 
synthetase reaction composed of MBP-BalhA2 treated with MBP-tagged BcerB/BalhCD 
produced tryptic fragments with two and three azole heterocycles, denoted by the red and purple 
colors, respectively. The 4+ charge state is shown and the number next to the peak corresponds to 
the number of heterocycles. The experimental and theoretical monoisotopic masses shown 
correspond to the three-azole ring species. 
 
 
Figure 2.15 MS/MS of the three-ring tryptic fragment of BalhA2. The b+ and y+ ions are 
labeled blue and orange, respectively. The observed fragmentation was annotated based on the 
residue number within the tryptic fragment. The stars signify heterocycle locations.  
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Figure 2.16 Thiazole ring order of BalhA2 with BcerB/BalhCD. Data were collected from a 
synthetase reaction of MBP-BalhA2 treated with MBP-tagged BcerB/BalhCD. The fragment 
ions observed for various ring intermediates are denoted by the b+ and y+ ion symbols. The 
number at the leftmost edge of the figure indicates the ring state. Cysteines are labeled based on 
the full length BalhA2. Black = 0 rings. Red = 1 ring. Green = 2 rings. Brown = 3 rings. The 
stars signify heterocycle locations. 
 
 
Figure 2.17 Thiazole ring order of BalhA2 with BcerBCD. Data were collected from 
synthetase reactions of MBP-BalhA2 treated with MBP-BcerBCD. The fragment ions observed 
for various ring intermediates are denoted by the b+ and y+ ion symbols. The number at the 
leftmost edge of the figure indicates the ring state. Cysteines are labeled based on the full length 
BalhA2. Black = 0 rings. Red = 1 ring. Green = 2 rings. Brown = 3 rings. The stars signify 
heterocycle locations. 
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Figure 2.18 ESI-MS of full length BcerA reaction. A synthetase reaction containing MBP-
BcerA treated with MBP-tagged BcerBCD was allowed to react for 22 h, while concurrently 
cleaved with TEV protease (red). Compared to the substrate only control (black), a mass loss 
indicative of 3 azole heterocycles and 1 azoline heterocycle was observed in the 5+ and 6+ 
charge states. 
 
 
Figure 2.19 Ring order of BcerA using BcerBCD. Data were collected from synthetase 
reactions of MBP-BcerA treated with MBP-tagged BcerBCD. The fragment ions observed for 
various ring intermediates are denoted by the b+ and y+ ion symbols. The number at the leftmost 
edge of the figure indicates the ring state. Cysteines are labeled based on the full length BcerA. 
Black = 0 rings. Red = 1 ring. Green = 2 rings. Brown = 3 rings. The stars signify heterocycle 
locations. 
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Figure 2.20 Ring order of BcerA using BcerB, BalhC and BalhD. Data were collected from 
synthetase reactions of MBP-BcerA treated with MBP-tagged BcerB/BalhCD. The fragment ions 
observed for various ring intermediates are denoted by the b+ and y+ ion symbols. The number at 
the leftmost edge of the figure indicates the ring state. Cysteines are labeled based on the full 
length BcerA. Black = 0 rings. Red = 1 ring. Green = 2 rings. Brown = 3 rings. The stars signify 
heterocycle locations. 
 
2.8 Effect of Substrate Truncations/Insertions on the Cyclodehydration Reaction 
 For the purposes of using combinatorial biosynthesis to generate conformationally 
restrained peptides (TOMMs) with desirable properties, it would be useful for the processing 
enzymes to also tolerate substrates of varied lengths, increasing the amount of peptide space one 
could survey. To probe the Balh TOMM biosynthetic ability to accept substrates of different 
lengths, a series of truncation and insertion substrates were generated. To generate the truncation 
substrates a stop codon was mutated into the sequence of BalhA1 using site-directed mutagenesis 
(i.e. G47* contains a stop codon at position 47 instead of the originally occurring glycine). The 
insertion substrates contain either the amino acid sequence GAG or GAGGAG after the 
predicted end of the leader sequence (…PDD) (Table 2.1). All of the substrates were accepted by 
the cyclodehydratase with varying efficiencies (Table 2.6). Truncation and insertion substrates 
that contained C40 (equivalent to C43 or C46 for the insertion substrates) were processed 
efficiently, and the order of ring formation was not altered greatly or at all for BalhA1-G47* and 
BalhA1-C54* (Figures 2.21 and 2.22). The processing rate of the truncated substrates lacking 
C40 was very similar to the rate of the single cysteine-containing NC substrates (excluding NC-
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A40C), again highlighting the regioselective, yet promiscuous, nature of the Balh TOMM 
enzymes. 
 
Table 2.6  Processing efficiency of BalhA1 truncations/insertions. a The truncations substrates 
have a stop codon (*) at the denoted location. Insertion substrates have the denoted amino acid 
sequence after the predicted end of the leader peptide (PDD). b % WT = (Substrate Vo / WT Vo) x 
100 
 
 
Figure 2.21 MS/MS fragmentation of BalhA1-G47* reaction intermediates. Data were 
collected from synthetase reactions of MBP-BalhA1-G47* treated with MBP-tagged 
BcerB/BalhCD. The fragment ions observed for various ring intermediates are denoted by the b+ 
and y+ ion symbols. The number at the leftmost edge of the figure indicates the ring state. 
Cysteines are labeled based on the full length BalhA1-G47*. Black = 0 rings. Red = 1 ring. 
Green = 2 rings. Brown = 3 rings. Grey = 4 rings. Light blue = 5 rings. The stars signify 
heterocycle locations. The two ring species showed an equal abundance of C31 and C34 as the 
second heterocycle, and the ions indicative of this are denoted by the asterisk. 
 
Substratea Vo (μM Pi min-1)  % WTb 
BalhA1 G30* 0.91 ± 0.02 4.5 
BalhA1 G36* 1.0 ± 0.1 4.9 
BalhA1 G42* 14.3 ± 0.4 71.0 
BalhA1 G47* 20.4 ± 0.8 101 
BalhA1 C54* 21.2 ± 0.3 105 
BalhA1 GAG ins 17.4 ± 0.9 86.1 
BalhA1 GAGGAG ins 19 ± 2 94 
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Figure 2.22 MS/MS fragmentation of BalhA1-C54* reaction intermediates. Data were 
collected from synthetase reactions of MBP-BalhA1-C54* treated with MBP-tagged 
BcerB/BalhCD. The fragment ions observed for various ring intermediates are denoted by the b+ 
and y+ ion symbols. The number at the leftmost edge of the figure indicates the ring state. 
Cysteines are labeled based on the full length BalhA1-C54*. Black = 0 rings. Red = 1 ring. 
Green = 2 rings. Brown = 3 rings. Grey = 4 rings. Light blue = 5 rings. The stars signify 
heterocycle locations. The two ring species showed an equal abundance of C31 and C34 as the 
second heterocycle, and the ions indicative of this are denoted by the asterisk. 
 
 
2.9 Evaluation of Unnatural Chimeric Substrates 
 To further explore the substrate tolerance of BcerB, BalhC and BalhD, the genes for two 
chimeric substrates were synthesized. These substrates harbor the BalhA1 leader peptide and an 
unnatural core peptide. BalhA1-Scramble contained residues 26-46 of BalhA1 in randomized 
order while BalhA1-McbA harbored a truncated core peptide of the microcin B17 precursor 
peptide (Figure 2.1). Based on the substrate processing rules elucidated earlier in this study, 
BalhA1-Scramble was predicted to have four thiazoles and one methyloxazoline installed after 
reaction with BcerB/BalhCD. We predicted that all the cysteines, with the exception of the two 
most C-terminal, would be converted to thiazoles. We also hypothesized that the most C-
terminal threonine would be cyclized to a methyloxazoline heterocycle, as BcerB had already 
been shown to not oxidize (methyl)oxazolines in vitro (Figure 2.1). The cysteine not expected to 
be cyclized in the scrambled region (C42) had a -1 cysteine, which we predicted upon cyclization 
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would prevent the formation of the bisheterocycle. Synthetase reactions followed by MALDI-
MS analysis resulted in five heterocycles on BalhA1-Scramble, as predicted (Figure 2.23). 
Moreover, LC-MS/MS allowed the localization of the four azole heterocycles to the most C-
terminal cysteines of the tryptic fragment and demonstrated that the rings were installed in an 
overall C- to N-terminal directional fashion (Figure 2.23). Unexpectedly, the bisheterocycle was 
indeed formed. Although this modification eluded prediction, the heterocycle at C42 was the last 
azole heterocycle to be installed and may proceed with a slow heterocyclization rate due to the 
thiazole heterocycle in the -1 position. Such bisheterocycle sites are critical for the activity of 
bleomycin and microcin B17.35, 36 Thus, combinatorial TOMM engineering efforts may find 
application for the production of artificial DNA intercalators and gyrase inhibitors. As with the 
BalhA2 substrate, it was not possible to localize the azoline ring; however, we presume its 
location to be T46. It is noteworthy that the one cysteine that remained unmodified had a -1 
threonine and +1 glycine, both of which would presumable decrease the rate of heterocyclization 
may provide an explanation for its inability to be cyclized.  
The second unnatural substrate tested was the BalhA1-McbA precursor peptide, which 
was expected to contain four thiazoles after reaction with BcerB/BalhCD (Figure 2.1). However, 
only three azole heterocycles were found (Figure 2.23). Again, LC-MS/MS was utilized to 
localize the heterocycles to the most C-terminal cysteines, which were installed in an overall C- 
to N-terminal directional fashion (Figure 2.23). Similar to the unmodified cysteine in BalhA1-
Scramble, the remaining cysteine had a -1 serine and a +1 glycine. As best illustrated with these 
unnatural chimeric substrates, the Balh TOMM biosynthetic enzymes have shown remarkable 
tolerance to unnatural core peptides.  
  
	  	   48 
 
Figure 2.23 MS of BalhA1-Scramble and BalhA1-McbA reactions. A. A synthetase reaction 
containing MBP-BalhA1-Scramble treated with MBP-tagged BcerB/BalhCD was allowed to 
react for 16 h and concurrently cleaved with TEV protease (red) before MALDI-TOF MS 
analysis. The black trace is the substrate only control. The +1 charge state is shown. The 
numbers over the peaks indicate successive losses of -20 (azole heterocycles), with the exception 
of ring 5 (-18, azoline heterocycle). The asterisk denotes a laser-induced artifact. B. Same as 
panel A, except BalhA1-McbA was used as the substrate. C. The amino acid sequence of the 
chimera substrates. All colored cysteines contained heterocycles derived from BcerB/BalhCD, 
and the color indicates the order of formation (Red- 1st, Green-2nd, Brown-3rd, and Grey- 4th). The 
predicted location of the azoline heterocycle is shown in blue. 
 
 
2.10 Conclusions 
Using a combination of MS and enzyme kinetics, the promiscuity of the thiazole/oxazole 
forming enzymes from Bacillus sp. Al Hakam has been evaluated. In vitro reconstitution of the 
cyclodehydratase and dehydrogenase resulted in five thiazoles on BalhA1. The design and 
deployment of a simplified substrate allowed a rapid and quantitative assessment of substrate 
chemo- and regioselectivity. Proper positioning of serine and threonine residues on an unnatural 
substrate showed that the biosynthetic enzymes were capable of catalyzing the formation of 
(methyl)oxazolines. The order of ring formation for multiple substrates proceeded with an 
overall C- to N-terminal directionality, which to the best of our knowledge has not been observed 
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previously in ribosomal peptide natural product biosynthesis. Characterization of a series of 
substrate mutants with varying flanking residues, including charged amino acids and 
truncations/insertions again illustrated the substrate flexibility and potential utility in 
combinatorial engineering. Processing of two artificial core peptides confirmed the promiscuity 
of these biosynthetic enzymes, which were processed in a highly predictable manner. In this 
work, we have identified a robust system capable of installing cysteine- and serine/threonine-
derived heterocycles onto variable precursor peptides, which was not limited to in vivo 
processing or reliant on other tailoring enzymes. Our findings exemplify the potential of the Balh 
TOMM synthetase as a platform for employing combinatorial biosynthesis to generate unnatural 
thiazole and oxazoline containing products with desired activities. 
 
2.11 Experimental 
2.11.1 Materials and General Methods.  
Unless otherwise specified, all chemicals were purchased from Fisher Scientific or 
Sigma-Aldrich. Oligonucleotides were purchased from Integrated DNA Technologies. 
Restriction enzymes were purchased from New England BioLabs (NEB). dNTPs were purchased 
from Promega. PfuTurbo DNA polymerase was purchased from Stratagene (now Agilent). DNA 
sequencing was performed by the Keck Biotechnology Center (University of Illinois at Urbana-
Champaign), Eton Biosciences, or ACGT, Inc. Methods regarding bioinformatics, basic 
molecular biology, protein overexpression and protein purification can be found in the 
Supporting Information. 
2.11.2 Synthetase Reaction. 
 In general, a precursor peptide (100 µM), dehydrogenase (10 µM), cyclodehydratase (10 
µM), and docking protein (10 µM) were added together with synthetase buffer [50 mM Tris pH 
7.4, 125 mM NaCl, 20 mM MgCl2, 2 mM adenosine triphosphate (ATP), and 10 mM 
dithiothreitol (DTT)]. When optimizing in vitro reaction conditions, supplementing the reaction 
with 50 µM FMN was found to produce a 2-fold rate increase in azole formation. Reaction 
products were analyzed using two different methods. TEV cleavage was done concurrently (1:50 
of µg of TEV protease: µg of total protein) or after the reaction (1:10 of TEV protease: protein at 
30 °C for 30 minutes). The samples were desalted by ZipTip (Millipore) according to the 
manufacturer’s specifications. Alternatively, the samples were trypsin digested using Sequencing 
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Grade Modified Trypsin (Promega) and analyzed by LCMS. Trypsin was resuspended according 
to the manufacturer’s specifications. Synthetase reactions (10 µL) were used for a 30 µL trypsin 
digestion reaction. TCEP was added to a concentration of 2 mM, and trypsin was used in a 1:40 
trypsin:total protein ratio. Trypsin digestions proceeded for at least 30 min at 30 °C. The samples 
were quenched using formic acid prior to LCMS analysis, with the final concentration being 
6.25% (v/v). 
2.11.3 Purine Nucleoside Phosphorylase Coupled Assay. 
 Quantitative kinetic measurements were conducted on a Cary 4000 UV/VIS 
spectrophotometer (Agilent). The substrate, synthetase buffer (50 mM Tris pH 7.4, 125 mM 
NaCl, 20 mM MgCl2, 2 mM ATP, and 10 mM DTT), 0.2 units purine nucleoside phosphorylase, 
and 20 nmoles of 7-methyl-6-thioguanosine (Berry and Assoc.) were allowed to equilibrate to 
room temperature. Immediately before beginning the assay, C- and D-proteins were added to an 
empty cuvette. For all the NC substrate analogs and other reported substrates, the initial rate was 
measured using 2 µM MBP-BalhC and MBP-BalhD with 100 µM substrate. For determination 
of the kinetic parameters, a range of substrate concentrations was used with 1-5 µM of MBP-
BalhC and MBP-BalhD. The remainder of the reaction mixture was used to initiate the reaction. 
Reaction progress was monitored at 360 nm. The concentration of phosphate was calculated 
based on the molar absorptivity of the product (11,000 M-1 cm-1). Initial rates were determined by 
plotting the data in Microsoft Excel. Error was calculated as the standard deviation of the mean 
(n ≥ 3). Nonlinear Michaelis-Menten regressions were conducted using Igor Pro version 6.1 and 
the error reported reflects the standard deviation from the curve fitting. 
2.11.4 HPLC MS/MS. 
All reverse-phase liquid chromatography-Fourier-transform mass spectrometry (FTMS) 
was carried out on an Agilent 1200 HPLC system with an autosampler connected directly to a 
ThermoFisher Scientific LTQ-FT hybrid linear ion trap, operating at 11 T. The mass 
spectrometer was calibrated weekly following the manufacturer’s protocol. 
 Trypsin digested samples were separated using a 1 x 150 mm Jupiter C18 column (300 Å, 
5 µM, Phenomenex). Samples were subjected to one of two methods. The first was a full scan 
followed by data-dependent MS/MS of the four most abundant peaks. Using this method, the 
MS/MS ions were detected in the FTMS with the following parameters: minimum target signal 
counts: 5,000; resolution: 50,000; m/z range detected: dependent on target m/z, default charge 
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state: 2, isolation width: 5 m/z, normalized collision energy (NCE): 35; activation q value: 0.40; 
activation time: 30 ms. The second method was used to determine the ring order, the MS/MS ion 
detection was carried out in the ion-trap mass spectrometer (ITMS). This method also utilized 
targeted MS/MS determined for various ring states and substrates. The following parameters 
were used: isolation width: 3 m/z, normalized collision energy (NCE): 35; activation q value: 
0.25; activation time: 30 ms. Data analysis was conducted using the Qualbrowser application of 
Xcalibur (Thermo-Fisher Scientific). 
2.11.5 Direct Infusion Analysis by ESI-MS or ESI-MS/MS 
Acetonitrile (ACN, 6.75 µL) was added to TEV cleaved synthetase reactions (25 µL). 
Precipitate was allowed to form for 5 minutes, which was then removed by centrifugation at 
16,060 x g (Sorvall Fresco Microcentrifuge). The supernatant (20 µL) was diluted with ddH2O 
(20 µL). The diluted sample was then desalted and concentrated by ZipTip (Millipore) according 
to the manufacturer’s specifications with the omission of acid from all solutions. The samples 
were eluted into 20 µL of 50% ACN (v/v). 
 Low-resolution analysis was conducted by injecting 15 µL onto an Agilent 1200 series 
HPLC operated at 0.5 ml/min at 50% ACN w/ 0.1% formic acid with no column to a single 
quadrupole mass analyzer (G1956B). Analysis was conducted in positive ion scan mode, 13 
L/min drying gas rate, 30 psig nebulizer pressure, 350 °C drying gas temperature and a 4000 V 
capillary voltage. Basic analysis was done using ChemStation, and the data were plotted using 
OriginPro 8.5. 
 High-resolution analysis was conducted using a ThermoFisher Scientific LTQ-FT hybrid 
linear ion trap, operating at 11 T. Samples were directly infused using an Advion Nanomate 100. 
MS/MS was conducted using identical settings as described above. 
2.11.6 MALDI-TOF Analysis 
 TEV cleaved peptides were analyzed using MALDI-TOF analysis on a Bruker Daltonics 
UltrafleXtreme MALDI TOF/TOF. All samples were desalted using a ZipTip according to the 
manufacturer’s specification and eluted directly onto the target into 4 µL of α-cyano-4-
hydroxycinammic acid. The samples were then allowed to dry under ambient conditions. All 
analyses were conducted using positive reflector mode. The instrument was calibrated before 
each use using a peptide calibration kit (AB SCIEX). Data were analyzed using FlexAnalysis. 
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2.11.7 Bioinformatic Analyses 
 Highly similar biosynthetic gene clusters were identified using BlastP with BalhD as the 
query sequence. Initial alignments were conducted using ClustalW2, and manually adjusted.37 
Percent identity and percent similarity were calculated based on ClustalW2 alignments. 
2.11.8 Molecular Biology Techniques 
Bacillus sp. Al Hakam genomic DNA was isolated by the method of phenol-chloroform 
extraction. The inserts for cloning the precursor peptides and enzymes were amplified by PCR 
from genomic DNA followed by PCR purification, using EconoSpin silica membrane columns 
(Epoch Life Science). The inserts and vector (modified pET28b vector containing an N-terminal 
maltose binding protein (MBP) tag followed by thrombin and TEV protease cleavage sites) were 
digested with the appropriate restriction endonucleases. The insert was PCR purified, while the 
vector was gel extracted from a 0.85% agarose gel, using a Gel Extraction Kit (Omega Bio-Tek). 
Ligation reactions were conducted using T4 DNA Ligase (NEB) and transformed in chemically 
competent DH5α cells, and plated on Luria Bertani (LB) agar plates with 50 µg/mL kanamycin. 
Colonies were chosen, grown up, and the plasmid DNA was isolated and submitted for DNA 
sequencing using a T7 terminator primer and a custom MBP forward primer (5' - 
ATGAAGCCCTGAAAGACG - 3'). 
The gene for the non-cyclizable version of BalhA1 was synthesized (GenScript) and 
subsequently subcloned into the pET28b-MBP vector as outline above. 
Site-directed mutagenesis was conducted using QuikChange as outlined in the 
manufacturer’s instructions.  
2.11.9 Overexpression and Purification of MBP Fusion Proteins. 
The desired constructs were transformed into chemically competent BL21(DE3)RIPL 
cells and selected with 50 µg/mL kanamycin. A single colony was used to start an overnight 
culture containing 50 µg/mL kanamycin and 35 µg/mL chloramphenicol. This starter culture was 
used to inoculate 1 L of Luria-Bertani (LB) medium.  For overexpression of the precursor 
peptides, these cells were aerated by shaking at 37 °C until OD600 of 0.8 was reached and then 
induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 1 h at 22 °C. Cultures 
expressing BCD proteins were grown to an OD600 of 0.6 and then induced with 0.4 mM IPTG for 
16 h at 22 °C. For overexpression of the C-protein, 50 µM ZnCl2 was added with the IPTG. For 
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overexpression of the B-protein, 50 µM riboflavin was added with the IPTG. The cells were 
harvested by centrifugation and stored at -20 °C until purification. 
Cell pellets were resuspended in MBP lysis buffer [50 mM Tris pH 7.5, 500 mM NaCl, 
2.5 % glycerol (v/v), 0.1 % triton-X (v/v)]. Lysozyme was added to a concentration 3-4 mg/mL. 
Phenylmethanesulfonyl fluoride, benzamidine, leupeptin, and E64 were added to prevent 
proteolytic degradation of the MBP-fusion proteins. Three rounds of sonication (30 s) followed 
by rocking at 4 °C (10 min) were conducted. The cellular debris was removed by centrifugation 
at 35 000 x g for 40 min at 4 °C. The supernatant was applied to amylose resin (NEB) and 
washed with 4 column volumes (CV) lysis buffer and 3 CV wash B buffer [50 mM Tris pH 7.5, 
400 mM NaCl, 2.5 % glycerol (v/v)]. Elution buffer (50 mM Tris pH 7.5, 150 mM NaCl, 10 mM 
maltose, 2.5 % glycerol (v/v)] was used to recover the MBP fusion protein. The protein solution 
was buffer exchanged 10-fold into storage buffer [50 mM HEPES pH 7.5, 300 mM NaCl, 2.5 % 
glycerol (v/v)] and concentrated using Amicon centrifugal filters (Millipore). Proteins were 
stored at -80°C until needed. The washes, elution and protein storage buffer all contained 1 mM 
tris (2-carboxyethyl) phosphine hydrochloride (TCEP) for precursor peptides and 0.5 mM TCEP 
for B, C, and D proteins. Protein concentration was quantified using absorbance at 280 nm, 
Bradford analysis, and in some cases BCA protein assay. Purity was assessed using a 
Coomassie-stained SDS-PAGE gel.  
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Chapter 3: Orchestration of Enzymatic Processing by Thiazole/Oxazole-Modified Microcin 
Dehydrogenases 
 
Adapted with permission from Melby, J. O., Li, X., and Mitchell, D. A. (2014) Orchestration of 
enzymatic processing by thiazole/oxazole-modified microcin dehydrogenases, Biochemistry 53, 
413-422. Copyright 2014 American Chemical Society. 
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Abstract 
 Thiazole/oxazole-modified microcins (TOMMs) comprise a structurally diverse family of 
natural products with varied bioactivities linked by the presence of posttranslationally installed 
thiazol(in)e and oxazol(in)e heterocycles. The detailed investigation of the TOMM biosynthetic 
enzymes from Bacillus sp. Al Hakam (Balh) has provided significant insight into heterocycle 
biosynthesis. Thiazoles and oxazoles are installed by the successive action of an ATP-dependent 
cyclodehydratase (C- and D-protein) and a FMN-dependent dehydrogenase (B-protein), which 
are responsible for azoline formation and azoline oxidation, respectively. Although several 
studies have focused on the mechanism of azoline formation, many details regarding the role of 
the dehydrogenase (B-protein) in overall substrate processing remain unknown. In this work, we 
evaluated the involvement of the dehydrogenase in determining the order of ring formation, as 
well as the promiscuity of the Balh and microcin B17 cyclodehydratases to accept a panel of 
noncognate dehydrogenases. In support of the observed promiscuity, a fluorescence polarization 
assay was utilized to measure binding of the dehydrogenase to the cyclodehydratase using the 
intrinsic fluorescence of the FMN cofactor. Ultimately, the noncognate dehydrogenases were 
shown to possess cyclodehydratase-independent activity. A previous study identified a conserved 
Lys-Tyr motif to be important for dehydrogenase activity. Using the tools developed in this 
study, the Lys-Tyr motif was shown to not alter complex formation with the cyclodehydratase 
nor the reduction potential. Taken with the known crystal structure of a homolog, our data 
suggest that the Lys-Tyr motif is of catalytic importance. Overall, this study provides a greater 
level of insight into the complex orchestration of enzymatic activity during TOMM biosynthesis. 
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3.1 Introduction 
TOMMs represent a subset of the larger ribosomally synthesized and post-translationally 
modified peptide class of natural products.1 Characterized TOMMs feature a diverse range of 
biological activities including DNA gyrase inhibitors, translation inhibitors, and hemolytic 
toxins.1-5 The defining feature of TOMMs are the presence of thiazol(in)e and oxazol(in)e 
heterocycles derived from cysteine, serine, and threonine residues on a ribosomally produced 
precursor peptide.6 Thiazole and oxazole biosynthesis occurs over two steps, the first being an 
ATP-dependent cyclodehydration to afford azoline heterocycles, which is catalyzed by the 
collective efforts of the C- and D-proteins (cyclodehydratase) encoded in TOMM biosynthetic 
gene clusters (Figure 3.1).7-10 Two-electron oxidation of the azoline by a FMN-dependent 
dehydrogenase (B-protein) affords the azole heterocycle.11 In addition to these core 
modifications, many TOMMs contain a variety of other post-translational modifications 
catalyzed by ancillary enzymes found in the gene cluster.6, 12-14 
 Early studies on microcin B17 biosynthesis laid a foundation for understanding the 
mechanistic underpinnings of thiazole and oxazole installation.10, 11, 15 While recent work has 
delved into the mechanistic enzymology and substrate processing details of the Balh and 
cyanobactin cyclodehydratases, relatively little is known regarding any potential role played by 
the dehydrogenase in orchestrating substrate processing.7-9, 16-18 Upon its initial heterologous 
expression and co-purification with a visibly yellow FMN cofactor, the B-protein was postulated 
to oxidize azolines to the corresponding azole.11, 15 In microcin B17 biosynthesis, the 
dehydrogenase (McbC, whose letter designation derives from its position within the gene cluster, 
not its function) formed a complex with the cyclodehydratase (McbB and McbD) and proved to 
be an essential component for peptide processing.15 In contrast, the dehydrogenase has been 
shown to be dispensable for azoline formation with the Balh and cyanobactin 
cyclodehydratases.7, 17, 18 Using both native and artificial substrates, it was shown that the Balh 
cyclodehydratase (BalhC/D) cyclized particular cysteines, serines and threonines (BalhA1, 5 
cysteines; BalhA2, 3 cysteines and 1 threonine).16, 17 However, the noncognate dehydrogenase 
from a highly similar biosynthetic gene cluster in Bacillus cereus 172560W, BcerB (78% 
identity/94% similarity to BalhB, which purifies with minimal FMN cofactor), was only capable 
of oxidizing thiazolines.17 The chemoselectivity for thiazolines was reminiscent of the 
dehydrogenase involved in patellamide biosynthesis, which oxidizes two thiazolines while 
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leaving two oxazolines intact.19 Another unique feature of the Balh TOMM was revealed upon 
determining the order of thiazole biosynthesis; processing by the BcerB/BalhC/BalhD complex 
occurred in an overall C- to N-terminal direction for the two substrates, BalhA1 and BalhA2 
(Figure 3.2). While this processing direction was unusual, it remained unclear if the 
cyclodehydratase or dehydrogenase governed the order of ring formation.17, 20   
 Bioinformatic analyses have now identified over 1000 TOMM gene clusters, which are 
found by conducting BLAST searches using the C- or D-proteins as the query sequence. Owing 
to the sequence similarity of the TOMM dehydrogenase to other non-TOMM dehydrogenases, 
BLAST searches using the B-protein as the query sequence to identify new TOMM clusters 
suffer from a high false-positive rate. Frequently, TOMM clusters lack a dehydrogenase 
altogether (e.g. trunkamide21) and such products contain exclusively azoline heterocycles, not 
azoles. A rare exception to this rule is illustrated by bottromycin, whose biosynthetic gene cluster 
lacks any recognizable dehydrogenase.22-25 Instead, it is postulated that the oxidation of the sole 
thiazoline to the thiazole occurs via an oxidative decarboxylation, which is plausible given that 
the thiazole derives from the most C-terminal cysteine of the core region of the peptide (Figure 
3.3).22, 23, 25 TOMM dehydrogenases belong to the nitroreductase superfamily (PFAM PF00881), 
which also includes FMN-dependent dehydrogenases involved in polyketide synthesis among 
other processes.26, 27 TOMM dehydrogenases can be found as a single domain protein or as a 
fusion to another protein involved in peptide maturation (e.g. PatG, involved in patellamide 
biosynthesis).28, 29 
 The ability of the Balh TOMM synthetase to exhibit cyclodehydratase and 
dehydrogenase activity independent of each other afforded the unique opportunity to explore the 
finer details of dehydrogenase activity. By decoupling cyclodehydratase and dehydrogenase 
activity, we were positioned to address long-standing questions regarding the individual roles of 
the cyclodehydratase and dehydrogenase in the order of substrate processing. Furthermore, the 
tolerance of noncognate dehydrogenases was explored in detail, along with an investigation into 
the chemoselectivity of the dehydrogenase. Our study further implicates a previously identified 
Lys-Tyr motif, conserved among TOMM dehydrogenases, in catalysis.    
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Figure 3.1 Synthesis of thiazole and oxazole heterocycles occurs over two distinct steps. 
First, the cyclodehydratase (C- and D- proteins) cyclizes cysteine, serine, or threonine residue 
into a thiazoline or oxazoline heterocycle through an ATP-dependent mechanism. Subsequently, 
a FMN-dependent dehydrogenase (B-protein) catalyzes the 2-electron oxidation to the azole 
heterocycle, resulting in a 20 Da mass loss from the unmodified amino acid. 
 
 
Figure 3.2 Dehydrogenase identity/similarity matrix and amino acid sequence of precursor 
peptides. A. Amino acid percent similarity (blue) and percent identity (green) matrix between 
dehydrogenases of interest to this study. ClustalW2 was used to calculate the pairwise identities 
and similarities.30 B. Amino acid sequence of the cognate precursor peptide(s) for each 
dehydrogenase utilized in this study. Known residues to be cyclized in vivo or in vitro are 
colored red. Only the BalhA1 and McbA precursor peptides were used in this study. 
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Figure 3.3 Three potential pathways for azole formation in ribosomal natural product 
biosynthesis. A. A possible polar mechanism for azoline dehydrogenation, which implicates the 
conserved Lys-Tyr motif in acid/base catalysis. B. Alternative radical mechanism for 
dehydrogenation that proceeds via a semiquinone radical intermediate. The data in this paper do 
not distinguish between the mechanisms drawn in panel A/B. C. Hypothesized oxidative 
decarboxylation mechanism for thiazole formation in the natural product bottromycin.22, 23, 25 The 
bottromycin biosynthetic gene cluster lacks a bioinformatically identifiable TOMM 
dehydrogenase. Cys: X = S, R = H; Ser: X = O, R = H; Thr: X = O, R = CH3. 
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3.2 Order of Azoline and Azole Ring Formation 
Azole formation by the Balh TOMM synthetase proceeds in an overall C- to N-terminal 
direction.17 An unresolved question was whether this processing direction was governed by the 
cyclodehydratase, the dehydrogenase, or by their collaboration. Due to chemical instability, 
routine LC-MS/MS cannot be employed to localize peptidic azolines, as such heterocycles 
rapidly hydrolyze and revert to the unmodified amino acid.31, 32 As an alternative approach, any 
unprocessed cysteines could be labeled using iodoacetamide, which would then be 
distinguishable from processed cysteines by LC-MS/MS.20, 33 To generate azoline intermediates, 
the BalhA1 precursor peptide was treated with the BalhC/D cyclodehydratase (dehydrogenase 
omitted). After a specified time, the reactions were quenched by the addition of trypsin and the 
unmodified cysteines were labeled with iodoacetamide. Subsequent acidification with formic 
acid hydrolyzed all thiazolines to cysteine. The modified and unmodified cysteines were then 
identified using LC-MS/MS (Figure 3.4). By this method, residues that were converted to 
thiazolines would be detected as an unmodified cysteine, while the residues labeled by 
iodoacetamide would indicate cysteines that did not undergo cyclodehydration. The order of 
azoline formation precisely followed the overall order of azole formation previously determined 
when the substrate was treated with the full consortium of TOMM synthetase proteins (BCD 
together).17 Irrespective of the presence of the dehydrogenase, Cys40 was cyclized first, followed 
by Cys31 and Cys34 in equal amounts, Cys45, and finally, Cys28 (Figure 3.5).  
The ability to decouple cyclodehydratase and dehydrogenase activity not only allowed 
the investigation of azoline order but also permitted the dissection of azole order of the 
dehydrogenase, BcerB. Upon adding BcerB to the penta-thiazoline of BalhA1 (BalhA1-5Tzn, 
pre-formed by BalhC/D), the order of oxidations en route to BalhA1-5Tzn could be monitored as 
in previous studies using LC-MS/MS17. Intriguingly, the processing order failed to follow azoline 
biogenesis. The first position to be oxidized was Tzn34, followed by an outward series of 
modifications simultaneously radiating towards the N- and C-termini (Figure 3.6). 
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Figure 3.4 Iodoacetamide labeling for azoline localization. In an ordered fashion, the 
cyclodehydratase installs azoline heterocycles onto the precursor peptide. Cysteines that have not 
undergone cyclodehydration were labeled with iodoacetamide. Acid-catalyzed hydrolysis reverts 
thiazolines back to cysteines. Localizing the unmodified and acetamide-labeled cysteines 
allowed the order of processing to be determined. 
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Figure 3.5 MS/MS fragmentation of BalhA1 azoline intermediates. BalhA1 reactions with 
BalhC/D to produce thiazoline-containing intermediates were treated with trypsin and 
iodoacetamide to identify unreacted cysteines. Subsequent addition of formic acid returned all 
thiazolines back to cysteine, at which point the samples were subjected to LC-FTMS/MS. The 
fragment ions observed for various ring intermediates are denoted by the b+ and y+ ion symbols. 
The leftmost numbers indicate ring state. Across the top, cysteines are numbered based on the 
sequence of full length BalhA1. Lightning bolts signify locations labeled with iodoacetamide. 
Asterisks denote ions containing a mixed population of two peptides. 
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Figure 3.6 MS/MS fragmentation of BalhA1 azole intermediates. Synthetase reactions 
containing BalhA1-5Tzn treated with BcerB were quenched by the addition of trypsin and 
subjected to LC-FTMS/MS. The fragment ions observed for various ring intermediates are 
denoted by the b+ and y+ ion symbols. The leftmost numbers indicate ring state. Across the top, 
cysteines are numbered based on the sequence of full length BalhA1. Stars signify thiazole 
locations, while a half star signifies that there are ions indicative of a thiazole as well as a free 
cysteine at that position. Asterisks denote ions containing a mixed population of two peptides. 
 
3.3 Permissive Nature of TOMM Dehydrogenases 
 As we have noted in our earlier reports,9, 17 the BalhB dehydrogenase purifies with 
minimal bound FMN cofactor (predominately apo), thus the above studies were conducted using 
a noncognate dehydrogenase from Bacillus cereus 172560W. Dubbed BcerB, this protein co-
purifies with near stoichiometric amounts of FMN and shares significant sequence similarity 
with BalhB (78% identity / 94% similarity).9, 17 It has also been shown with the TOMM from 
Clostridium botulinum that a noncognate dehydrogenase, SagB from Streptococcus pyogenes 
(41% identity / 80% similarity to ClosB), can successfully substitute for the cognate 
dehydrogenase, ClosB, during in vitro reconstitution of clostridiolysin S.34 In both of the cases 
mentioned above, the substituted dehydrogenase was closely related to the cognate 
dehydrogenase. To test the ability of more distant dehydrogenases to successfully complement 
thiazole/oxazole biosynthesis, a series of diverse dehydrogenases were cloned, expressed, 
purified, and tested for activity using the Balh and Mcb TOMM cyclodehydratases (Table 3.1, 
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Figures 3.2, 3.7, and 3.8). All noncognate dehydrogenases formed thiazoles in conjunction with 
the Balh cyclodehydratase (Figure 3.7). The order of azole formation was also determined for 
reactions containing the TOMM dehydrogeneases from Bacillus amyloliquefaciens FZB42 and 
Clavibacter michiganensis subsp. sepedonicus (BamB and CmsB, respectively). Both 
dehydrogenases followed a highly similar pathway as BcerB when processing BalhA1-5Tzn 
(Figures 3.6 and 3.9). In stark contrast to the flexible nature of the Balh enzymes, only reactions 
with the cognate dehydrogenase (McbC) produced heterocycles when testing the Mcb 
cyclodehydratase (McbB/D). The observed dehydrogenase intolerance of the Mcb 
cyclodehydratase suggests that the noncognate dehydrogenases tested are not capable of forming 
a product trimeric complex with McbB/D, which has been shown to be essential for 
thiazole/oxazole biosynthesis.15  
 
 
 
Table 3.1 Bioinformatic data for the dehydrogenases used in this study. Shown are the 
dehydrogenase designations, along with their respective locus tags, GI numbers, producing 
organism, and percent identity/similarity to BalhB. The dehydrogenase responsible for microcin 
B17 biosynthesis (E. coli) was assigned a letter designation for its position within the 
biosynthetic gene cluster, not its function. 
 
Dehydrogenase Locus Tag GI number Organism %Identity/%Similarity to BalhB
BcerB bcere0005_53170 228601410 Bacillus cereus 172560W 78/94
BamB RBAM_007480 154685203 Bacillus amyloliquefaciens FZB42 19/60
CmsB Cms_0547 170780985 Clavibacter michiganensis subsp. sepedonicus 16/51
McbC MCBC_ECOLX 126808 Escherichia coli 16/59
PagB PF0001 18891897 Pyrococcus furiosus DSM 3638 21/61
SaciB Saci_0525 70606348 Sulfolobus acidocaldarius DSM 639 23/66
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Figure 3.7 The Balh cyclodehydratase tolerates noncognate dehydrogenases. The reactions 
containing the indicated reagents were allowed to react for 16 h at 25 °C and then analyzed using 
MALDI-TOF-MS after formic acid hydrolysis of thiazoline heterocycles. The numbers at the top 
indicate the number of azole heterocycles. The asterisk denotes a laser-induced artifact.  
 
	  	   68 
 
Figure 3.8 Dehydrogenase intolerance of the Mcb cyclodehydratase. The reactions 
containing the indicated reagents were allowed to react for 16 h at 25 °C and then analyzed using 
MALDI-TOF-MS after formic acid hydrolysis of azoline heterocycles. The numbers at the top 
indicate the number of azole heterocycles. The asterisk denotes a laser-induced artifact. 
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Figure 3.9 The order of azole formation on BalhA1-5Tzn by CmsB and BamB. A. 
Synthetase reactions containing BalhA1-5Tzn treated with CmsB were quenched by the addition 
of trypsin and subjected to LC-FTMS/MS. The fragment ions observed for various ring 
intermediates are denoted by the b+ and y+ ion symbols. The leftmost numbers indicate ring state. 
Across the top, cysteines are numbered based on the sequence of full length BalhA1. Stars 
signify thiazole locations. A half star signifies that there are ions indicative of a thiazole as well 
as a free cysteine at that position. Asterisks denote ions containing a mixed population of two 
peptides. B. Same as A except using BamB. 
 
3.4 Monitoring TOMM Synthetase Complex Formation by Fluorescence Polarization 
 Because noncognate dehydrogenases successfully oxidized BalhA1 in the presence of 
BalhC/D, while all the dehydrogenases (except McbC) tested failed to complement McbB/D, we 
hypothesized that the dehydrogenases might be able to form a complex with BalhC/D but not 
with McbB/D. To test this, we utilized a fluorescence polarization-based binding assay that 
capitalizes on the intrinsic fluorescence of the FMN cofactor. A similar assay has been employed 
to study the interaction of luciferase and lumazine.35, 36 An increase in the fluorescence 
polarization would occur upon binding of the dehydrogenase to the cyclodehydratase complex. 
Fluorescence polarization was measured using a fixed concentration of BcerB with increasing 
concentrations of BalhC/D (Figure 3.10). As the concentrations of BalhC/D were increased, 
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significant fluorescence polarization was observed and the apparent Kd of 1.7 ± 0.2 µM aligned 
with the previously reported Kcomplex measured for McbC to McbB/D (1.8 ± 0.8 µM).15 All other 
non-cognate dehydrogenases were also subjected to this binding assay, yet no binding was 
observed (data not shown).  
 
Figure 3.10 Fluorescence polarization of BcerB and the Balh cyclodehydratase. The 
fluorescence polarization of the FMN cofactor of BcerB (1 µM) was measured with varying 
concentrations of the Balh cyclodehydratase. A dose-response fit of the data provided the 
apparent Kd. The error reported for each individual data point corresponds to the standard 
deviation of three technical replicates, while the error reported for the apparent Kd derives from 
the error associated with curve fitting. 
 
3.5 Cyclodehydratase-Independent Dehydrogenation 
To reconcile the dehydrogenase activity observed in the absence of detectable binding of 
noncognate dehydrogenases (with the exception of BcerB) to BalhC/D, the ability of such 
dehydrogenases to act upon BalhA1-5Tzn in a cyclodehydratase-independent fashion was 
measured. Initially, the requirements for efficient dehydrogenation were monitored using BcerB. 
After forming BalhA1-5Tzn with BalhC/D and concomitant TEV cleavage, acetonitrile was 
added to the reaction mixture to precipitate large proteins while leaving BalhA1-5Tzn in 
solution. After centrifugation, decantation, and evaporation of the acetonitrile supernatant by 
vacuum centrifugation, various combinations of BcerB, BalhC and BalhD were added (Figure 
3.11). As a control, addition of BalhA1 to these samples did not result in any detectable 
enzymatic processing, indicating that the acetonitrile-based removal of BalhC/D was adequate 
and any residual enzymes were inactive (Figure 3.11). To deconvolute the mixture of 
heterocycles, formic acid was added to selectively hydrolyze the thiazolines, leaving thiazoles 
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intact (Figure 3.12).16, 37 From these experiments, it became clear that dehydrogenation efficiently 
occurred only when the dehydrogenase was present with both cyclodehydratase proteins (i.e. 
BalhC/D), although thiazoline oxidation intermediates were observed when individual 
components of the cyclodehydratase were supplied separately (Figure 3.12). The 
cyclodehydratase-independent activity was then measured using the entire panel of noncognate 
dehydrogenases (Figure 3.13). Contrary to BcerB, all other noncognate dehydrogenases 
exhibited roughly the same processing efficiency, regardless of the presence of BalhC/D (Figure 
3.7 and 3.13). 
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Figure 3.11 Minimal requirement for dehydrogenase activity. BalhA1-5Tzn was treated with 
various components of the TOMM synthetase. All samples contained supplemental FMN (50 
µM). The reactions were allowed to react for 16 h at 25 °C prior to analysis by MALDI-TOF-
MS. During the preparation of BalhA1-5Tzn, BalhC/D were precipitated using acetonitrile. To 
demonstrate that all of the BalhC/D had been removed or inactivated, additional BalhA1 was 
added to a reaction (+A1), and remained unmodified after the reaction (m/z 6041). This suggests 
that the processing seen for the subsequent reactions was the result of the indicated proteins. The 
addition of BcerB alone to BalhA1-5Tzn (+B) did not result in any azole formation, evidenced 
by the lack of mass shift (m/z 5951). Addition of BcerB, in conjunction with BalhC (+BC) or 
BalhD (+BD), resulted in 1 thiazole or 2 thiazoles as the major species (m/z’s 5949, 5947 
respectively). However, efficient dehydrogenation only occurred when BcerB, BalhC, and BalhD 
were all present, as evidenced by the loss of 10 Da (5 x 2H, m/z 5941). To remove any 
unmodified thiazoline heterocycles, all the reactions were hydrolyzed and analyzed again using 
MALDI-TOF-MS (Figure 3.12). 
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Figure 3.12 Minimal requirement for dehydrogenase activity after acid hydrolysis. BalhA1-
5Tzn was treated with varying combinations of synthetase components. The reactions were 
allowed to react for 16 h at 25 °C and then analyzed using MALDI-TOF-MS after formic acid 
hydrolysis of thiazoline heterocycles. The numbers above the spectra indicate the number of 
azole heterocycles. Asterisks denote laser-induced artifacts. 
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Figure 3.13 Noncognate dehydrogenase activity towards BalhA1-5Tzn. BalhA1-5Tzn and 
various dehydrogenases were allowed to react for 16 h at 25 °C. To remove any unreacted 
thiazoline heterocycles, formic acid (10% v/v) was added and allowed to react for at least 1 h 
prior to MALDI-TOF-MS analysis. The numbers above the spectra indicate the number of azole 
heterocycles. The asterisk denotes a laser-induced artifact. 
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3.6 Universal Importance of the Conserved Lys-Tyr Motif in TOMM Dehydrogenases 
 Sequence alignment of TOMM dehydrogenases reveals a highly conserved Lys-Tyr motif 
(Figure 3.14).16 Based on Protein DataBank entry 3EO7 (a putative nitroreductase from 
Anabaena variabilis ATCC 29413), which is the most similar protein with a published structure 
(12% identity/ 51% similarity to McbC), the Lys-Tyr motif is located near the FMN cofactor 
(closest distance is 5.6 Å, Figure 3.15). Mutagenesis of the Lys-Tyr motif failed to alter the FMN 
loading, further suggesting that the Lys-Tyr motif is not directly involved in FMN binding 
(Figure 3.16). A previous study, which replaced the Lys201 and Tyr202 of McbC to Ala resulted 
in inactive protein during microcin B17 in vitro reconstitution reactions, suggestive of a potential 
catalytic role.16 McbC-K201A and -Y202A were also inactive towards BalhA1-5Tzn (Figure 
3.17). The equivalent Lys-Tyr motifs in the TOMM dehydrogenases from the Gram-positive 
Bacillus cereus 172560W (BcerB) and the thermoacidophilic archaeon Sulfolobus 
acidocaldarius DSM 639 (SaciB) were mutated to Ala and screened for activity. BcerB-K185A 
exhibited reduced activity, as indicated by the formation of up to four thiazoles in an end-point 
essay, while BcerB-Y186A and the double mutant (K185A/Y186A) were catalytically inactive 
(Figure 3.18). Similar to McbC, the single and double mutants to the Lys-Tyr motif in SaciB 
abolished activity (Figure 3.18). Increased protein concentrations (5-50 µM dehydrogenase) and 
reaction times (24 h) failed to restore detectable activity for the BcerB, SaciB, and McbC 
mutants. In further support for a catalytic role, BcerB-K185A and -Y186A were tested for their 
ability to form a complex with BalhC/D. Using the FMN-based fluorescence polarization assay, 
BcerB-K185A/Y186A was found to bind with similar affinity as wild type BcerB (Figure 3.19). 
Taken together, our data suggest that the Lys-Tyr motif plays a role in catalysis by the 
dehydrogenase. 
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Figure 3.14 Multiple sequence alignment of TOMM dehydrogenases. The dehydrogenases 
used in this study were aligned using ClustalW2.30 A known FMN-binding motif is highlighted 
in yellow, which is lacking in McbC. The invariant Lys-Tyr motif originally identified in a 
previous study is highlighted in green.9 Residues mutated in this study are colored red.  
 
  
BalhB      FNNRKSVE-ELEIRTRISFEKLSNLLHFSYGYVNK------------EHNVAPSAGAKYP 118 
BcerB      LNNRKSVE-ELEIRTRIRFETLSNLLHFSYGYINK------------PHSAAPSAGGKYP 117 
McbC       VINISSSHNFSRERLPSGINFCDKNKLSIRTIEKLLVNAFSSPDPGSVRRPYPSGGALYP 139 
CmsB       LAARRSAEPR-TLGRPVELAELATVLRLAYGPR-G---------DGTPRRFVPSGGGLYP 170 
BamB       IQNRRSIE-Q-FNGGSTTLAQLSTILQGSYGLIER---------PEGPRRPIPSGGALYP 138 
PagB       IVTRRSIR-T-FSYEPIKLNELSVLLKLSSGVVLI----QDEENHSIYHRSFPTAGGLNS 138 
SaciB      MKRRHSSR-A-FRRERINLNKISSLLWYSVGVKEI--------ENGIQFRMFPSAGNLAE 105 
              : *            :  :  :*  :                       *:.*     
 
BalhB      ISIYIVIFNVE--NL--EQGIYYYNKEQDTLELIRKGEYR---DAINNLY-----IDNNH 166 
BcerB      INIYIAVFNVE--NL--EQGIYYYDREQDVLDMIRRGDFR---ESINNLY-----VDNTH 165 
McbC       IEVFLCRLSENTENWQAGTNVYHYLPLSQALEPVATCNTQ-------SLYRSLSGGDSER 192 
CmsB       LDLHVVARSVV--GL--EPGIHQLDPLEETLVDVSGLDRD---GQLARFRRAAPSLMAPI 223 
BamB       LDLYVVSNKVD--SL--EKGLYHFDPYRKGLVHLGEYSEE---DFGRIML------QEEA 185 
PagB       CHVYLISLNVD--DL--PFGSYYYDPLTHELIKIEEYQISQKNEFLDTLVKVLG--NQEW 192 
SaciB      TEVYLISLYT---DL--EKGVYHYDPVEGSLDVLSNDL-D-EELMLQAIK---N--SLPD 153 
             :.:                :        *  :              :                
 
BalhB      IHSSSFIMFHVADLNKTSNKYEDRGYKLIHLDMGHLSQNLYLLSSAQQLGIRAIFGLYEN 230 
BcerB      IHSSSFIMFHAANLDQTSSKYADRGYKLIHLDMGHLSQNLYLLSSAQQLGIRAIFGLYEN 229 
McbC       LGKPHFALVYCIIFEKALFKYRYRGYRMALMETGSMYQNAVLVADQIGLKNRVWAGYTDS 256 
CmsB       PETAAVTVVITGSFERSRCKYGLRGYRLTLLEAGHVGQNALLVATALGLPVLGWVGFVDH 287 
BamB       VKDFSFAVIISASFWRSRFKYGHRSYRFIFIEAGHLMQNMILLATAQCIQSRPYGGFIDD 249 
PagB       IRTAGLILIITGDYSKIRLKYGDRGYRYLLLEAGHIMQNFYLIASMLNLGVCSIGGFYDD 256 
SaciB      ITFVPLIILLTSLYWKPMVKYGNRGARFSLIDTGIVIENFYLVATALGLGISAIGGFNDD 217 
                . :.      :   **  *. :   :: * : :*  *::    :      *  :    
 
BalhB      KVNEFLEI-DGENEFVLLSH-VFGGIKYPTPVTMDTKFSDIYYENEEIESE- 279 
BcerB      KVNDFLEL-DGENEFVLLSH-VFGGIKLSTPITMDTKFSDIYYENEETKSEG 279 
McbC       YVAKTMNL-DQRTVAPLIVQ-FFGDVNDDK-CLQ------------------ 287 
CmsB       ELDAV-LGLDGVTQSSLYAI-SFGGADPGARRFADEEASHD----------- 326 
BamB       ELMDLIGGHNGVDDAPIYTL-VAGT--------------------------- 273 
PagB       YIAKLIHV-DNTNELVLY-LGGMGKLV------------------------- 281 
SaciB      FFNKLIGV-GMEKGEVVIGMLVVGEE-------------------------- 242 
            .  
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Figure 3.15 Non-TOMM dehydrogenase crystal structure highlighting the Lys-Tyr motif. A 
ribbon diagram of a putative nitroreductase from Anabaena variabilis ATCC 29413 (PDB entry 
3EO7). The TOMM dehydrogenase Lys-Tyr motif aligns to 3EO7-R175 and -Y176, whose side 
chains are shown in stick with green carbons. The FMN cofactor is also shown in stick but with 
yellow carbons. The closest distance between R175 and Y176 and the FMN cofactor is displayed 
as a yellow dotted line and was measured to be 5.6 Å. 
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Figure 3.16 UV/Vis spectra of TOMM dehydrogenases. A UV/Vis spectrum for each 
dehydrogenase used in this study was collected at 50 µM total protein concentration. The 
intensity of the FMN peaks (λmax = 440-460 nm) reflects the FMN content after heterologous 
expression and purification from E. coli for a particular dehydrogenase. Based on the molar 
absorptivity of FMN (12,500 M-1 cm-1), a dehydrogenase with 100% loading would have an 
absorbance of 0.625 at λmax. The subtle inconsistency in the shape of the spectra at 380 nm is due 
to a source changeover (deuterium UV lamp to Vis lamp) within the spectrophotometer. 
 
 
 
Figure 3.17 McbC-K201A and -Y202A lack dehydrogenase activity. Synthetase reactions 
containing either wild-type McbC or the indicated mutant proceeded for 16 h at 25°C. 
Subsequently, all azolines were hydrolyzed by acidification with formic acid prior to MALDI-
TOF-MS analysis. Asterisks denote laser-induced artifacts. The numbers above the spectra 
indicate the number of azoles.  
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Figure 3.18 Dehydrogenase activity of Lys-Tyr mutants. A. Synthetase reactions containing 
BcerB and the indicated mutants were conducted and allowed to react for 16 h at 25 °C. 
Subsequently, all azoline heterocycles were hydrolyzed using formic acid prior to MALDI-TOF-
MS analysis. B. Same as in A, except reactions contained SaciB and its Lys-Tyr mutants. The 
numbers above the spectra indicate the number of azole heterocycles. Asterisks denote laser-
induced artifacts. 
 
 
Figure 3.19 Binding of BcerB-K185A/Y186A to BalhC/D. The fluorescence polarization of 
the FMN cofactor of BcerB-K185A/Y186A (1 µM) was measured with varying concentrations 
of the BalhC/D (black). The binding curve for wild-type BcerB is shown in blue. These data 
indicate that the Lys-Tyr motif is not integral for synthetase complex formation as evidenced by 
a highly similar binding curves upon comparison to wild-type BcerB. The point of lowest 
polarization for BcerB-K185A/Y186A and BcerB were normalized to 0 mP. The error reported 
for each individual data point corresponds to the standard deviation of three technical replicates. 
 
	  	   80 
3.7 Comparison of TOMM Dehydrogenase Reduction Potentials 
 It was shown previously that while BcerB was an efficient thiazoline oxidase, this protein 
was unable to convert oxazolines to oxazoles, irrespective of the presence of BalhC/D.17 A 
possible explanation for the lack of activity towards oxazolines could arise from a difference in 
reduction potential compared to other B-proteins that produce oxazoles. To measure reduction 
potentials, UV/Vis spectra were collected while the FMN cofactor was chemically reduced using 
sodium dithionite (Figure 3.20). Addition and subsequent monitoring of the redox indicator dye, 
phenosafranine, allowed calculation of the dehydrogenase reduction potentials.38 Using this 
method, initial studies were focused on BcerB and McbC (oxidizes four oxazolines during 
microcin B17 maturation), which gave identical reduction potentials (Table 3.2).11 The reduction 
potential of BamB provided further evidence that BcerB does not harbor significantly different 
electrochemical properties compared to other TOMM dehydrogenases and as such, does not 
explain the observed selectivity towards thiazolines. Similarly, an altered reduction potential of 
the Lys-Tyr mutants could provide an explanation for the dearth of catalytic activity observed. 
However, the reduction potential of McbC-Y202A was not statistically different from BcerB 
(Table 3.2), further implicating the Lys-Tyr motif in enzymatic catalysis (Figure 3.3). 
 
Figure 3.20 The reduction potential of McbC as measured by phenosafranine titration. A, 
Upon chemical reduction of the FMN cofactor by sodium dithionite, the visible absorbance of 
McbC was decreased (arrows). The absorbance at 525 nm arises from the presence of the redox 
indicator dye, phenosafranine, which also looses visible absorbance upon reduction. B, The 
fraction of oxidized (ox) and reduced (red) flavin and phenosafranine were calculated from the 
spectra shown in panel A. The reduction potential of the dehydrogenase was calculated from the 
y-intercept by plotting the log(ox/red) BcerB versus the log(ox/red) for phenosafranine.38 Since 
the reduction of phenosafranine is a two-electron process, a slope of one indicates that the 
reduction of the FMN cofactor in McbC involves two electrons.  
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Table 3.2 Reduction potentials of TOMM dehydrogenases. The redox potential of the listed 
TOMM dehydrogenases were measured by chemically reducing the FMN cofactor with sodium 
dithionite in the presence of phenosafranine, an indicator dye, and monitoring the reduction of 
both by UV/Vis spectroscopy.38 The error reported is the standard deviation of three independent 
measurements. 
 
3.8 Summary and Outlook 
 During microcin B17 biosynthesis, the full trimeric complex of McbBCD is required for 
thiazole/oxazole ring formation.15 Fortunately, the cyclodehydratase from Balh does not require 
the dehydrogenase for activity, which allowed us to examine cyclodehydration separately from 
dehydrogenation. While the order of thiazoline formation by BalhC/D (Figure 3.5) followed the 
previously reported order for azole formation (generated from a full BCD reaction), the order of 
azole formation when the dehydrogenase was presented with a penta-azoline substrate (BalhA1-
5Tzn) proved drastically different. During BalhA1-5Tzn processing, BcerB first oxidized the 
thiazoline at Cys34 (Tzn34) and subsequently proceeded outward toward the C- and N-termini 
simultaneously (Figure 3.6). Other dehydrogenases processed the BalhA1-5Tzn substrate in a 
similar fashion (Figure 3.9). A potential explanation could be that the dehydrogenases recognize 
a specific motif within the precursor peptide, which based on distance constraints, orients Tzn34 
closest to the active site. However, both the microcin B17 and streptolysin S TOMM 
dehydrogenases (McbC and SagB, respectively) were shown to have little affinity for their 
cognate precursor peptides.15, 39 The aberrant order of cyclodehydratase-independent 
dehydrogenase activity also demonstrated that while BalhA1-5Tzn was a competent 
intermediate, it did not follow the native biosynthetic processing order. When the full 
biosynthetic complex was present, azole order proceeded in an overall C- to N-terminal direction 
and exhibited a distributive behavior, which was determined by the detection of intermediates 
with varying numbers of thiazole heterocycles.17 As such, we propose a biosynthetic pathway 
where dehydrogenation immediately follows cyclodehydration at every modified position.  
Protein Redox Potential (mV)
BcerB -277 ± 4
McbC -277 ± 2
BamB -280 ± 3
McbC Y202A -272 ± 1
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The ability of noncognate dehydrogenases to substitute for the native dehydrogenase does 
not appear to be universal in TOMM biosynthesis. With the Balh cyclodehydratase, every 
dehydrogenase tested could install thiazoles onto the BalhA1 substrate in the presence of 
BalhC/D (Figure 3.7), but only the native McbC dehydrogenase was tolerated during McbA 
processing (Figure 3.8). During in vitro reconstitution of microcin B17 biosynthesis, the three 
McbBCD proteins are each essential; omission of any protein abrogates all detectable enzymatic 
activity.15 Co-immunoprecipitation studies demonstrated that McbBCD form a heterotrimeric 
complex in which each component performs a unique function during azole formation.9, 11 
Therefore, if a noncognate dehydrogenase fails to successfully form a productive heterotrimeric 
complex with McbB/D (cyclodehydratase), no heterocycle formation would be expected occur. 
The ability of the noncognate dehydrogenases to complement the Balh cyclodehydratase 
suggested a catalytically active trimeric complex was formed between the dehydrogenases and 
cyclodehydratase. To provide evidence for complex formation between noncognate 
dehydrogenases and the Balh cyclodehydratase, a fluorescence polarization assay utilizing the 
intrinsic fluorescence of the FMN cofactor was employed to monitor binding. Surprisingly, only 
BcerB, a dehydrogenase from a nearly identical biosynthetic gene cluster, in conjunction with 
BalhC/D produced a fluorescence polarization curve indicative of complex formation (Figure 
3.10). The instability of McbBCD at high concentration without their MBP fusion partner 
precluded the monitoring of fluorescence polarization between McbC and McbB/D. The inability 
to detect an increase in fluorescence polarization using noncognate dehydrogenases suggested 
that there was cyclodehydratase-independent dehydrogenase activity.  
To garner further support for the dehydrogenase activity in the absence of a 
cyclodehydratase, we monitored dehydrogenase activity towards BalhA1-5Tzn in the absence of 
BalhC/D. To prepare this substrate, synthetase reactions were initiated with BalhA1 and 
BalhC/D. After completion of the reaction, acetonitrile was added to precipitate large 
polypeptides (i.e. BalhC and BalhD) while leaving BalhA1 derivatives in solution. After removal 
of the acetonitrile, BalhA1-5Tzn was subjected to various enzymatic reactions. As expected, 
efficient dehydrogenation only occurred when all the biosynthetic enzymes were added (BCD), 
but a minimal amount of activity was detected when BcerB was present with either BalhC or 
BalhD (Figure 3.12). BcerB alone had no detectable activity when presented with BalhA1-5Tzn 
(Figures 3.11 and 3.12). However, the other TOMM dehydrogenases were able to catalyze azole 
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formation in the absence of BalhC/D (Figure 3.13). This result provided an explanation for the 
inability to detect binding between the noncognate dehydrogenases (with the exception of 
BcerB) and BalhC/D while still being able to catalyze azole formation (Figure 3.13). It appears 
that all the dehydrogenases tested, excluding BcerB, exhibit nonspecific azoline oxidation. 
A previous study identified a conserved Lys-Tyr motif (Figure 3.14) that abolished the 
dehydrogenase activity of McbC.16 In the process of evaluating the biochemical determinants of 
azoline oxidation, the importance of the Lys-Tyr motif was further established in two other 
distantly related TOMM dehydrogenases (BcerB and SaciB). Mutation of either the Lys or the 
Tyr within the SaciB motif eradicated enzymatic activity in our assays (Figure 3.18). In BcerB, 
the K185A mutation had reduced activity as indicated by the detection of predominantly a three 
thiazole heterocycle species of BalhA1. However, BcerB-Y186A and -K185A/Y186A were 
devoid of activity (Figure 3.18). In all cases, mutation of the Lys-Tyr motif did not alter the 
FMN content of the dehydrogenase (Figure 3.16). Using the fluorescence polarization assay, 
BcerB-K185A/Y186A was found to form a complex with BalhC/D (Figure 3.19), indicating that 
the Lys-Tyr motif did not play a critical role in the protein-protein interaction. Another possible 
explanation for the loss of activity was an altered reduction potential; however, the potentials of 
McbC-Y202A and BcerB were not significantly different (p > 0.1). Based on the crystal structure 
of the closest homolog (PDB: 3EO7), it appeared the Lys-Tyr motif was poised to participate in 
catalysis, given its proximity to the active site (Figure 3.3 and 3.15). Taken together with our 
fluorescence polarization assays, FMN loading, and electrochemical titrations, the loss of activity 
in three distinct TOMM dehydrogenases supports a catalytic role for these residues (Figure 
3.3).16 A more detailed kinetic analysis of the Lys-Tyr mutants will be necessary to 
unequivocally establish a catalytic role for these residues. 
Interestingly, the Balh cyclodehydratase can cyclize cysteine, serine, and threonine 
residues to their respective azoline heterocycles16, 17, yet BcerB lacks the capability to convert 
(methyl)oxazolines to (methyl)azoles. Owing to the greater aromatic character of a thiazole 
relative to an oxazole, the oxidation of a thiazoline is more thermodynamically favorable than 
oxazoline oxidation.40 Therefore, one way to chemoselectively oxidize thiazolines would be to 
finely tune the electrochemical potential of the dehydrogenase. However, our measurement of 
TOMM dehydrogenase reduction potentials fails to explain the observed chemoselectivity of 
BcerB, as the values measured were not significantly different than dehydrogenases known to 
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form oxazoles (Table 3.2). The observed chemoselectivity must then derive from the ability of 
BcerB to discriminate between thiazolines and oxazoline by some other mechanism. A possible 
explanation is a difference in pKa between the α-hydrogens of a thiazoline versus an oxazoline. 
Base-catalyzed removal of the α-hydrogen may be rate determining in dehydrogenation reactions 
(Figure 3.3).11 
In conclusion, the ability to discriminate between cyclodehydratase and dehydrogenase 
function afforded the opportunity to study the order of both azoline and azole ring formation, 
which, in the case of Balh, was dictated by the cyclodehydratase. Testing the limit of noncognate 
dehydrogenase swapping with the Balh cyclodehydratase demonstrated that most noncognate 
dehydrogenases do not bind the cyclodehydratase and nonspecifically oxidize the azoline-
containing substrate. Furthermore, a conserved Lys-Tyr motif within the dehydrogenase was 
found to be critical for activity in distantly related TOMM dehydrogenases, which is postulated 
to play a role in acid/base catalysis. Through measurement of the reduction potential of a panel 
of dehydrogenases, the chemoselectivity of BcerB for thiazoline heterocycles does not result 
from a tuned redox potential and instead discriminates thiazoline from oxazoline at the substrate 
level. 
 
3.9 Experimental  
3.9.1 General Methods 
Unless otherwise specified, all chemicals were purchased from Fisher Scientific or 
Sigma-Aldrich. Oligonucleotides were purchased from Integrated DNA Technologies. 
Restriction enzymes were purchased from New England BioLabs (NEB). dNTPs were purchased 
from Genscript. PfuTurbo DNA polymerase was purchased from Agilent. Sequencing grade 
trypsin was from Promega. DNA sequencing was performed by the Carver Biotechnology Center 
(University of Illinois at Urbana-Champaign) or ACGT, Inc. 
 
3.9.2 Molecular Biology Techniques 
  The plasmids containing the Mcb and Balh/Bcer proteins have been described 
previously.15, 17 All other proteins were cloned into a modified pET28b plasmid containing MBP, 
followed by a thrombin and TEV protease cleavage sites, as described previously.3 Briefly, the 
dehydrogenases were amplified from genomic DNA using cloned Pfu DNA polymerase and the 
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relevant primers (Table 3.3). The amplicons were then PCR purified prior to a double restriction 
enzyme digest using BamHI and NotI. After gel purification of the amplicons, along with a 
similarly digested pET28b-MBP plasmid, the DNAs were ligated with T4 DNA Ligase (NEB). 
Site-directed mutagenesis was conducted using the Quikchange method (Agilent). 
 
 
Table 3.3 Oligonucleotide sequences. The direction the primer binds the particular gene are 
described as forward (f) and reverse (r). The restriction site for primers used for cloning are 
provided in parenthesis, while the restriction sequence is bolded and italicized. Primers used for 
site-directed mutagenesis have the mutated codon(s) underlined. 
 
3.9.3 Overexpression and Purification of Fusion Proteins 
 All proteins were expressed and purified as fusions to maltose binding protein (MBP) as 
described previously.9, 17 Proteolytical removal of MBP from was also performed as per previous 
reports.9, 17 
 
3.9.4 General Synthetase Reactions 
For Balh synthetase reactions, the precursor peptide (20-100 µM), B-protein (0 or 5-50 
µM), C-protein (1-10 µM), and D-protein (1-10 µM) were combined in synthetase buffer (50 
mM Tris, pH 7.4, 125 mM NaCl, 20 mM MgCl2, 2 mM ATP, and 10 mM DTT) with concurrent 
Oligonucleotide Sequence
CmsB f (BamHI) AAAAGGATCCATGAGCACCATCGAGACCGACGC
CmsB r (NotI) AAAAGCGGCCGCTCAGTCATGGGAGGCCTCCTCGTC
BamB f (BamHI) AAAAGGATCCATGAAAGAGATTGAAAGGCATGCCACTAATTTGG
BamB r (NotI) AAAAGCGGCCGCTCATGTTCCTGCAACTAAAGTATATATAGGGGCATC
SaciB f (SalI) AAAAGTCGACAATTGAATCCTTTTGAGAGGTTTTATCTAGATAC
SaciB r (NotI) AAAAGCGGCCGCTCATTCCTCTCCCACTACCAA
BcerB-K185A f GCCAATCTTGATCAAACAAGTAGTGCATACGCAGATAGGGGATATAAGTT
BcerB-K185A r AACTTATATCCCCTATCTGCGTATGCACTACTTGTTTGATCAAGATTGGC
BcerB-Y186A f CTGCCAATCTTGATCAAACAAGTAGTAAAGCCGCAGATAGGGGATA
BcerB-Y186A r TATCCCCTATCTGCGGCTTTACTACTTGTTTGATCAAGATTGGCAG
SaciB-K173A f TTATACTGGAAGCCGATGGTTGCATATGGAAATAGAGGAGCCAG
SaciB-K173A r CTGGCTCCTCTATTTCCATATGCAACCATCGGCTTCCAGTATAA
SaciB-Y174A f CTTATACTGGAAGCCGATGGTTAAAGCTGGAAATAGAGGAGCCAG
SaciB-Y174A r CTGGCTCCTCTATTTCCAGCTTTAACCATCGGCTTCCAGTATAAG
BcerB-K185A/Y186A f GCCAATCTTGATCAAACAAGTAGTGCAGCCGCAGATAGGGGATA
BcerB-K185A/Y186A r TATCCCCTATCTGCGGCTGCACTACTTGTTTGATCAAGATTGGC
SaciB-K173A/Y174A f TATACTGGAAGCCGATGGTTGCAGCTGGAAATAGAGGAGCC
SaciB-K173A/Y174A r GGCTCCTCTATTTCCAGCTGCAACCATCGGCTTCCAGTATA
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TEV protease treatment to remove the MBP fusion partner (1 µg protease: 50 µg protein). 
Reactions were allowed to proceed for 16 h at 25 °C. In reactions containing the B-protein, FMN 
(50 µM) was added to compensate for incomplete or inconsistent FMN loading during 
heterologous expression and purification. Precursor peptides containing only azoline 
heterocycles were generated from reactions that omitted the dehydrogenase. Synthetase reactions 
with the microcin B17 synthetase proteisn were conducted in a similar fashion as in the case of 
Balh, except those reactions had 20 µM McbA, 20 µM dehydrogenase, 5 µM McbB, and 5 µM 
McbD. 
 
3.9.5 Azoline Localization 
 Synthetase reactions lacking the B-protein (100 µM BalhA1, 5 µM BalhC and 5 µM 
BalhD) were quenched after 30, 150, or 210 min by the addition of trypsin (1 µg trypsin to 25 µg 
total protein) for 1 h at 30 °C. Subsequently, iodoacetamide was added to a final concentration of 
20 mM, and the labeling of uncyclized Cys residues was allowed to proceed for at least 30 min at 
25 °C with minimal exposure to light. The samples were then acidified using formic acid (6% 
v/v) and the azolines localized via LC-MS/MS as described below. 
 
3.9.6 HPLC MS/MS 
All reverse-phase LC-FTMS was performed using an Agilent 1200 HPLC system with an 
autosampler connected directly to a ThermoFisher Scientific LTQ-FT hybrid linear ion trap, 
operating at 11 T. The mass spectrometer was calibrated weekly following the manufacturer’s 
protocol. Trypsin digested samples were separated using a 1 × 150 mm Jupiter C18 column (300 
Å, 5 μM, Phenomenex). After a full scan detected in the FTMS, the MS/MS parent ions were 
manually selected and ion detection was carried out in the ion-trap mass spectrometer. The 
following parameters were used: isolation width, 3 m/z; normalized collision energy, 35; 
activation q value, 0.25; activation time, 30 ms. Data analysis was conducted using the 
Qualbrowser application of Xcalibur (Thermo-Fisher Scientific). 
 
3.9.7 Determination of the Order of Azole Ring Formation 
 Generation of the penta-thiazoline BalhA1 (BalhA1-5Tzn) was accomplished using 
synthetase reactions lacking the B-proteins (50 µM BalhA1, 5 µM BalhC, 5 µM BalhD, and 1 µg 
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TEV protease: 25 µg total protein). Upon complete formation of BalhA1-5Tzn (as judged by 
MALDI-TOF-MS), BcerB (5 µM) and FMN (50 µM) were then added to the reaction and 
allowed to proceed for either 4 or 45 minutes. Reactions were quenched by the addition of 
trypsin (1 µg trypsin: 25 µg total protein) for 1 h at 30 °C and subsequently acidified using 
formic acid (6% v/v) prior to HPLC MS/MS. 
 
3.9.8 MALDI-TOF MS Analysis 
 All samples for MALDI-TOF-MS were desalted and concentrated by C18 ZipTip 
(Millipore) according to the manufacturer’s protocol. Samples were eluted in a saturated solution 
of CHCA matrix in 50:50 H2O: acetonitrile with 0.1% (v/v) trifluoroacetic acid. After the 
samples were allowed to dry under ambient conditions, they were analyzed using a Bruker 
Daltonics UltrafleXtreme MALDI-TOF/TOF using positive reflector mode. The instrument was 
calibrated using a peptide calibration kit (AB SCIEX). Data were analyzed using FlexAnalysis. 
 
3.9.9 Fluorescence Polarization Assay  
Fluorescence polarization was conducted using a FilterMax F5 Multi-Mode Microplate 
Reader (Molecular Devices). The dehydrogenase (1 µM) and varying concentration of the C- and 
D-proteins were added to a 384-well black polystyrene microplate (Corning) and allowed to 
equilibrate for 30 min prior to measurement. For all samples, the autofluorescence of the C- and 
D-proteins were used for background correction. A sigmoidal dose-response curve fitting was 
conducted using OriginPro9. 
 
3.9.10 Dehydrogenase Reduction Potentials Measurement 
The reduction potential for various TOMM dehydrogenases were determined as 
described by Massey.38 The dehydrogenase (300 µM BcerB and 100 µM other dehydrogenases), 
benzyl viologen (2 µM) and phenosafranine (10 µM) were added to a 10 mL round bottom flask 
and the final volume was brought to 2 mL using protein storage buffer [50 mM HEPES pH 7.5, 
0.3 M NaCl, 2.5 % glycerol (v/v)]. The protein solution was degassed using a Schlenk line and 
subsequently introduced into an anaerobic chamber where the protein was allowed to equilibrate 
for 30 minutes while stirring. UV/Vis spectra were acquired using an Agilent 8453 spectrometer 
(Agilent Technologies). Sodium dithionite (1-5 µL of 10 mM) was employed to chemically 
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reduce FMN and phenosafranine. After sodium dithionite addition, the solution was stirred for 5 
minutes prior to recording another UV/Vis spectrum. This process was repeated until both FMN 
and phenosafranine were fully reduced. Using the absorbance measurements of FMN (440-450 
nm) and phenosafranine (520 nm), a plot of log(ox/red) phenosafranin versus log(ox/red) 
dehydrogenase was used to calculate the reduction potential of the dehydrogenases. 
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Appendix A: PDF Reprints of Other Coauthored Publications 
 
A.1 Structure Determination and Interception of Biosynthetic Intermediates for the 
Plantazolicin Class of Highly Discriminating Antibiotics 
 
Reprinted with permission from Molohon, K. J., Melby, J. O., Lee, J., Evans, B. S., Dunbar, K. 
L., Bumpus, S. B., Kelleher, N. L., and Mitchell, D. A. (2011) Structure determination and 
interception of biosynthetic intermediates for the plantazolicin class of highly discriminating 
antibiotics, ACS Chem Biol 6, 1307-1313. Copyright 2011 American Chemical Society. 
 
I aided in the collection, interpretation, and figure generation of high-resolution MS and NMR 
data. I also purified and confirmed the predicted structure of Bacillus pumilus plantazolicin. 
	   93 
 
	   94 
	   95 
	   96 
	   97 
	   98 
	   99 
 
  
	   100 
A.2 YcaO Domains Use ATP to Activate Amide Backbones During Peptide 
Cyclodehydrations 
 
I coauthored a manuscript with Kyle L. Dunbar and Douglas A. Mitchell entitled “YcaO 
Domains Use ATP to Activate Amide Backbones During Peptide Cyclodehydrations”, which 
was published in Nature Chemical Biology.1 All material is reproduced with permission from 
Nature Publishing Group.  
 
I performed initial 31P-NMR experiments using the Balh enzymes and Michaelis-Menten kinetic 
experiments for BalhA1NC-C40. I also collected high resolution MS data and MS/MS data used 
to localize the BalhD installed dehydrations.  
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A.3 Engineering Unnatural Variants of Plantazolicin Through Codon Reprogramming 
Reprinted with permission from Deane, C. D., Melby, J. O., Molohon, K. J., Susarrey, A. R., and 
Mitchell, D. A. (2013) Engineering unnatural variants of plantazolicin through codon 
reprogramming, ACS Chem Biol 8, 1998-2008. Copyright 2013 American Chemical Society. 
 
I collected, analyzed, and generated figures for all high resolution MS and MS/MS data, which 
was utilized to structurally characterize plantazolicin variants. 
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A.4 Structural and Functional Insight into an Unexpectedly Selective N-Methyltransferase 
Involved in Plantazolicin Biosynthesis 
 
I coauthored a manuscript with Jaeheon Lee, Yue Hao, Patricia M. Blair, Vinayak Agarwal, 
Brandon J. Burkhart, Satish K. Nair, and Douglas A. Mitchell entitled “Structural and functional 
insight into an unexpectedly selective N-methyltransferase involved in plantazolicin 
biosynthesis”, which was published in Proceedings of the National Academy of Sciences of the 
United States of America.2 All material is reproduced with permission from PNAS.  
 
I collected, analyzed, and generated a figure for the high-resolution MS and MS/MS data, which 
was used to structurally characterize the BamL reaction product.    
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A.5 Nucleophilic 1,4-Additions for Natural Product Discovery 
Reprinted with permission from Cox, C. L., Tietz, J. I., Sokolowski, K., Melby, J. O., Doroghazi, 
J. R., and Mitchell, D. A. (2014) Nucleophilic 1,4-additions for natural product discovery, ACS 
Chem Biol 9, 2014-2022. Copyright 2014 American Chemical Society. 
 
I collected, analyzed, and generated figures for all high resolution MS and MS/MS data, which 
was utilized to structurally characterize cyclothiazomycin C. 
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A.6 Structural Investigation of Ribosomally Synthesized Natural Products by Hypothetical 
Structure Enumeration and Evaluation Using Tandem MS 
 
I coauthored a manuscript with Qi Zhang, Manuel Ortega, Yanxiang Shi, Huan Wang, Weixin 
Tang, Douglas A. Mitchell, and Wilfred A. van der Donk entitled “Structural investigation of 
ribosomally synthesized natural products by hypothetical structure enumeration and evaluation 
using tandem MS”, which was published in Proceedings of the National Academy of Sciences of 
the United States of America.3 All material is reproduced with permission from PNAS.  
 
I contributed high-resolution MS data from BalhA2 reactions with BcerB/BalhC/D, which were 
utilized to test the structural scoring algorithm. 
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A.7 Structure, Bioactivity, and Resistance Mechanism of Streptomonomicin, an Unusual 
Lasso Peptide from an Understudied Halophilic Actinomycete 
 
Reprinted from Chemistry and Biology, 22, Mikhail Metelev, Jonathan I. Tietz, Joel O. Melby, 
Patricia M. Blair, Lingyang Zhu, Itamar Livnat, Konstantin Severinov, Douglas A. Mitchell, 
Structure, Bioactivity, and Resistance Mechanism of Streptomonomicin, an Unusual Lasso 
Peptide from an Understudied Halophilic Actinomycete, 12031-12036, Copyright 2015, with 
permission from Elsevier.  
 
I collected, analyzed, and generated figures for all high-resolution MS and MS/MS data, which 
was utilized to structurally characterize streptomonomicin.  
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